US3814097A - Dressing - Google Patents

Dressing Download PDF

Info

Publication number
US3814097A
US3814097A US00326474A US32647473A US3814097A US 3814097 A US3814097 A US 3814097A US 00326474 A US00326474 A US 00326474A US 32647473 A US32647473 A US 32647473A US 3814097 A US3814097 A US 3814097A
Authority
US
United States
Prior art keywords
pad
sheet
fibres
dressing
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00326474A
Inventor
D Ganderton
Ainsh J Mc
G Varney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Application granted granted Critical
Publication of US3814097A publication Critical patent/US3814097A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/00051Accessories for dressings
    • A61F13/00063Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A61F13/05
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00089Wound bandages
    • A61F2013/0017Wound bandages possibility of applying fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023Drug applicators using microneedles

Definitions

  • a dressing for administering a drug through the skin of a host comprising a reservoir for the drug and, located between the reservoir and the skin of the host when the dressing is in use. a pad provided with tiny spikes. These tiny spikes augment the absorption of the drug without causingirritution- 10 Claims, 2 Drawing Figures PATENTEDJUN 41914 III HHIIIIIIVIIIIIIILLLL IHIH'HHHHIHHII
  • This invention relates to a dressing for application to the skin.
  • it relatesto a dressing the primary use of which is not toprotect, or apply medication to, a wound or lesion, but in the administration of a pharmacologically active material to man or an animal.
  • pharmacologically active materials including drugs and medicinal products
  • topical application does not usually result in the pharmacologically active material becoming distributed throughout the body'of the host, and not all pharmacologically active materials may be administered by mouth. Injection is an inconvenient method of administration, especially if it has to be done frequently, and there is a need for an alternative.
  • An essential component of this dressing is a pad or plaster, provided with minute spikes, which is located in contact with the skin.
  • a pad comprising a sheet of material provided with tiny fibres projecting from at least one face of the sheet, the fibres being sufficiently rigid and projecting sufficiently from one face of the sheet such that upon application of that face of the sheet to the skin of a host, the fibres penetrate the skin to permit a liquid formulation of a pharmacologically active material, when present, to pass into the host and become distributed throughout the body of the host.
  • the inventionthus provides the basis of a dressing which can be used as an alternative to injection for the administration of a pharmacologically active material.
  • the number of fibres projecting from a unit area of the sheet may vary widely, but in the preferred embodiments, a multitude of fibres are used. Thus, for example, while some patches may have as few as 4 fibres per cm others may have as many as, or more than, 100 fibres per cm depending upon the diameter of the fibres; it being necessary that the fibres be spaced apart sufficiently to penetrate the skin.
  • the fibres will be made from material different from that of the sheet,-and in such a case, the fibres are necessarily located within the sheet as well as projecting from a face of the sheet. However, the fibres may be made of the same material as the sheet and simply project from the sheet.
  • Particularly useful such materials are, for example,
  • plasticised or unplasticised homopolymeric thermo plastics for example polyvinylchloride, polyvinylbutyral, polyethylene, polyamides, for example nylon, or cellulosics such as cellulose acetate; plasticised or unplasticised copolymeric thermoplastics, for example ethylene vinyl acetate; cross-linked water soluble polymers, for example polyvinylacetate or polyvinylpyrrolidone; rubbers, both natural and synthetic, for example polyisobutylene or polybutadiene; or foams, for example polyurethane foam, polyester foam or cellulose foam.
  • Preferred plastics materials for the sheet are cellulose acetate or nylon.
  • the sheet may also be made of metal, for example stainless steel, which may either be provided with fibres in the form of fine stainless steel tubes or projections of metal left round the edges of holes punched in the metal sheet.
  • a former for example a naturally spiky material such as a nettle or delphinium leaf may be coated with a metal to give a pad according to the invention, or-a pad prepared from other materials may be coated with metal to strengthen the fibres.
  • the fibres may be made of any material the surface of which is inert to body tissue and which is sufficiently strong when in the form of tiny fibres to penetrate the stratum corneum under the conditions in which the complete dressing is used.
  • Particularly suitable such materials are, for example, inorganic materials, for example a glass, carbon, alumina, zirconia or silicon nitride; organic materials, for example nylon or polyparabenzamide; or metals, for example stainless steel.
  • a bio-degradable material may be used.
  • the type of material chosen for any particular use will depend upon the site at which the complete dressing is to be applied,the nature of the drug to be administered and any other features associated with that particular use of the complete dressing.
  • a reservoir of pharmacologically active material is arranged'to dispense that material on to that surface of the pad remote from the projecting fibres.
  • the pad must be permeable to a liquid formulation of a pharmacologically active material.
  • This permeability may be achieved by using fibres in the form of tiny tubes, usually called capillary tubes, by using a sheet of material provided with a number of transverse holes, or by using an intrinsi of the desired liquid formulation. Any method of combination of methods of rendering the pad permeable may be used depending upon whether solid or hollow fibres are used and whether or not an intrinsically'permeable sheet is used, but the use of hollow fibres is considered to be desirable.
  • the precise diameter of the fibres is not critical provided that they can penetrate the stratum coneum, but it is preferred that the diameter be in the range 8 pm. to pm. unless the ends of thefibres are sharpened in which case, the diameter of the end of the fibre is preferably in the range 8 am. to 100 am.
  • Thelength of fibre which projects from the sheet is, however, important since it must be longenough to penetrate the stratum corneum, but not be so long that serious irritation is caused. In this context, a penetration of at least 20 ,um. is desirable, and a penetration of 1,000 pm. is probably the maximum which can be tolerated, depending upon the site at which the pad is located.
  • the fibres therefore should project from the sheet for a dis tance within the above range, and for preference; within the range 50-500 um.
  • the fibres should be aligned so that they project from that face of the 3 as an angle of approximately 45-90 to the face of the sheet.
  • any liquid formulation of a pharmacologically active material may be used in conjunction with the pad of the invention provided that the formulation has a sufficiently low viscosity to pass through the pad by the means provided.
  • the formulation has a sufficiently low viscosity to pass through the pad by the means provided.
  • suspensions and creams can be used with the appropriate pad.
  • a pad according to the invention may be constructed by any suitable method.
  • the fibres may be laid individually on a work base and cemented together using a solution of a plastics material as defined above to form a sheet con-v taining the fibres.
  • Several such sheets may then be joined to form a block which on being sliced normal to the fibres, produces .a sheet containing transverse fibres.
  • the fibres can be exposed to any desired length.
  • the fibres may be drawn directly on to a drum coated with plastics material and while still on the drum coated with the sameplastics material to give a sheet similar to that produced by hand.
  • a pad according to the invention can be'used to assist the absorption of a topically applied formulation of a pharmacologically active material, for example a cream or gel, by being placed over the applied formulation.
  • a pharmacologically active material for example a cream or gel
  • the pad need not be permeable.
  • the principal use envisaged for a pad according to the invention is as part of a dressing for the administration of a pharmacologically active material to man or an animal.
  • a dressing for the administration of a pharmacologically active material to a host comprising a pad as previously defined in accordance with the invention in'which the pad is permeable to a liquid formulation of a pharmacologically active material, and a reservoir fora liquid formulation of a pharmacologically active material so located that the pharmacologically active material, when present, can pass from the reservoir and through the pad.
  • FIG. I is'a diagrammatic representation of a vertical section of one embodiment I and I
  • FIG. II is a diagrammatic representation of a vertical section of another embodiment.
  • the dressing comprises a relatively rigid case I of metal or hard plastics material in the shape of an inverted shallow dish provided with a rim 2.
  • a pad according to the invention in the form of a sheet of plastics material 3, provided with tiny fibres 4 projecting from the lower face of the sheet 3.
  • the projection of the fibres 4 from the sheet 3 is much exaggerated in order'to render it visible.
  • the space formed between the pad and the case 1 forms a reservoir 5, and .at the upper part of case 1 (the base of the inverted dish) is located a means for filling the reservoir in the form of ahole which is closed by a plug 6, made of relatively soft material, for example'neoprene, which is capable of re-sealing after a needle has been passed through and then withdrawn from the plug.
  • a plug 6 made of relatively soft material, for example'neoprene, which is capable of re-sealing after a needle has been passed through and then withdrawn from the plug.
  • straps 7 Secured to the case 1 are straps 7 which extend from each side of the case 1.
  • the dressing is secured upon the skin of the host to whom a phannacologically active material is to be administeredby means of the straps 7 so'that the fibres 4, projecting from the sheet 3 are held against the surface of the skin.
  • a liquid formulation of the pharmacologically active materiaL'usually in the form of a solution, is filled into the reservoir 5 through the needle of a hypodermic syringe inserted through the plug 6.
  • the dressing illustrated is ically active material has been administered through similar to that of FIG. I in that it comprises a relatively I rigid case 1, and a pad, formed from a sheet of plastics material 3 with fibres 4, forming a reservoir 5 which can be filled with a liquid formulation of a pharmacologically active material via a plug 6 located in the side wall of the case 1.
  • the dressing of FIG. II is however provided with means for applying pressure to the formulation of pharmacologically active material, when such is present in the reservoir 5, in the form of a chamher 8 in theupper part of the case 1, separated from the reservoir 5 by a flexible membrane'9, and capable of retaining gas under a pressure greater than atmospheric pressure.
  • FIG. II the dressing illustrated is ically active material has been administered through similar to that of FIG. I in that it comprises a relatively I rigid case 1, and a pad, formed from a sheet of plastics material 3 with fibres 4, forming a reservoir 5 which can be filled with a liquid formulation of a pharmacologically active material via a plug 6
  • the chamber 8 can contain granules of sodium bicarbonate, preferably coated with a polymer, so that on admitting an acidic solution to the chamber 8 via the needle of a hypodermic syringe inserted through the plug 10, carbon dioxide gas is slowly generated and a pressure is exerted on the-membrane 9.
  • FIG. II is used in the same way as that of FIG. I, being secured to the host by straps 7.
  • the reservoir may be distinct from the pad, for example the walls of the reservoir may be separate from the case and/or the pad.
  • the reservoir could be, for example, a sachet of plastics material permeable to the liquid formulation of the pharmacologically active material and located within the space formed by the case and the pad in the embodiments illustrated, or it could be formed from the case and a permeable .wall extending across the case along, the inside of the pad. Alternatively, it could be in the form of, for example,
  • the reservoir may be a gel which may be impregnated with pharmacologically active material as desired.
  • the dressing When the dressing is provided with pharmacologically active material and is in use, that material will diffuse from the reservoir to the pad, and the rate at which this takes place isdependent upon the nature of the reservoir wall and its thickness, both of which can be varied as desired. In the cases illustrated where the pad itself forms one wall of the reservoir, the rate of diffusion is dependent upon the pad and its fibres.
  • the dressing may also be provided with a layer of ma terial between the reservoir and the pad to act as a diffusion layer to control the rate of delivery of the pharmacologically-active material to the pad.
  • the dressing may also be provided with means whereby pressure is exerted on the formulation of pharmacologically active material toincrease the rate at. which it passes from the reservoir and/or through the pad.
  • means whereby pressure is exerted on the formulation of pharmacologically active material toincrease the rate at. which it passes from the reservoir and/or through the pad.
  • Alternatives to the specific means illustrated are, for example, a distendible reservoir which can be filled under pressure; a spring-loaded reservoir which exerts a mechanical or hydrostatic pressure on its contents; or a pressure bandage which is used both to retain the dressing in place and to exert pressure on the contents of the reservoir.
  • the dressing may be secured to the skin of a host by means of adhesive tape or an elasticated net, and such securing means may form part of the dressing itself.
  • the area surrounding the pad for example the rim 2 in the embodiments illustrated or partof the straps 7, may bear an adhesive tosecure that area to the skin of the host.
  • the rate of diffusion of the liquid formulation of pharmacologically active material from the reservoir to the host is dependent upon the nature of the reservoir and the nature of the pad.
  • the total amount of material administered to the host is also dependent upon the surface area of the reservoir and pad.
  • a dressing according to the present invention as well as being capable of being used to administer pharmacologically active materials normally given by injection, can also be used to administer such materials continuously over an extended period.
  • Such amethod of administration enables the variation in the concentration of a pharmacologically active material in the blood of a host, produced by administration of the material at intervals, to be reduced, and this advantage is not limited to materials which are normally administered by injection.
  • tides for example polypeptide hormones and synthetic polypeptides possessing some at least of the pharmacological properties of the hormones, for example insulin,
  • oxytocin bradykinin, gastrin, pentagastrin or urogastrone; or prostaglandins.
  • a dressing as defined together with aliquid formulation of a pharmacologically active material.
  • Pads according to the invention are illustrated by the following Examples, and such pads may be tested for efficacy by comparing the transfer of a solution containing a pharmacologically active material through skin in the presence of the pad with the transfer effected in its absence. Both in vitro and in vivo methods may be used. The following is an example of such a test:
  • EXAMPLE 1 Fibres in the form of glass capillary tubes 40 pm. in external diameter and approximately 15 cm. long, were laid individuallyon a glass plate parallel to each other and about 0.5 mm. apart. The ends of the tubes were retained on two strips of double-sided adhesive tape located approximately 13 cm. apart. A solution in acetone of cellulose acetate containing acetyl triethyl citrate as plasticiser was brushed on to the aligned glass tubes and the solvent allowed to evaporate. The process was repeated until a film 0.5l mm. thick had been built up. Several such films were prepared and cut into squares approximately 2.5 cm. X 2.5 cm.
  • the product was a square of cellulose actate sheet having a centre portion 2 cm. in diameter provided with tiny glass capillarytubes about 0.5 mm. apart extending through the sheet and projecting from one surface by about 100 um.
  • a platinum crucible was filled with small spheres of E-glass and the whole heated to l,O C. to melt the glass. The crucible was then maintained at l,200 C. for about 2 hours after which the glass was ready tobe drawn into a fibre on a rotating drum.
  • the drum was first coated with a layer of plastics material, usually cellulose acetate, by application of a solution of the plastics material in acetone to the surface of the drum and evaporation of the'acetone.
  • a fibre of glass was then drawn from the tip of the crucible and wound on to the drum through a guide. The drum was rotated, and the guide'wasallowed to traverse the coated surface of the drum at a speed to give the required density of wound fibre, usually 1 fibre/mm.
  • the fibre was then cut, and a coat of plastics material applied to the wound fibre using asolution in acetone. After the acetone had evaporated, the film of plastics material with the glass fibres aligned within it was stripped from the drum. The operation was repeated many times, and then all the sheets so obtained were then interleaved with sheets of the same. plastics material of the same thickness but not containing glass fibres.
  • the sheets were treated with a small amount of acetone and/or methanol as solvent, and by applying pressure to the sheets, a block was built up in which the glass fibres were all aligned in the same direction and evenly spaced apart. The block was then sectioned transverse to the glass fibres to give small sheets of material about 1-2 mm.
  • the diameter of the, drawn fibre could be varied by variation in the speed of rotation of the drawing drum.
  • a drawing'speed of 0.5 metre/sec. produced a fibre of about 40 um. diameter
  • a drawing speed of 3 metres/sec. produced a fibre of 15 pm. diameter. 0
  • the extent of projection of the fibre from the surface of the sheet of plastics material could be varied by controlling the extent of the etching of the plastics material.
  • the fibres did not all project to the same extent, but nevertheless, a variation in average projection from about pm. to 250 ptm., with individual variation from 50 pm. to 400 um. could be achieved.
  • a glass tube of approximately 1 mm. external diameter was drawn through a heater at 800 C. and wound on to a drum coated with plastics material asabove.
  • sheets of plastics material provided with tiny, projecting hollow glass fibres were produced.
  • pads By using the techniques described above. a considerable variety of pads'comprising a sheet of plastics material provided with a multitude of tiny glass fibres projecting from one face, thereof have been preparedjA representative selection of such pads is set out below:
  • a sheet of EN 58B stainless steel. 26 am. in thickness was cut into discs about 1.5 cm. in diameter and 20 holes punched into each disc by means of a sewing needl mounted in the chuck of a bench drill which was lowereii filfoiifirotatiohIiii'tothe steel'disc to a controlled extent.
  • the holes so produced were 78 pm. in diameter and a burr 104 pm. in length was left projecting from one side of the steel sheet.
  • the net result was a pad, consisting of a sheet of steel provided with tiny fibre-like spikes projecting from one surface, and being permeable to liquid by virtue of the holes.
  • a pad for augmenting the absorption of a liquid formulation of a pharmacologically active material through the skin of a host comprising a sheet of material, a plurality of tiny hollow fibres passing through the sheet and projecting from at least one face of said sheet, said fibres having an external diameter at the end of the fibre in the range 8 pm. to 100 um. and projecting from said sheet from 20 pm. to 1,000 ;.m and a means on one side of said sheet material constituting a means for supplying said liquid material.
  • a dressing for administering a liquid formulation of a pharmacologically active material to a host through the skin of said host comprising a pad according to claim 1 said supply means comprising a reservoir for receiving a liquid formulation of the phannacologically active material located to permit said liquid formulation, when present, to pass from said reservoir and through said pad to the skin of said host.
  • a dressing according to claim 5 wherein the reservoir comprises a case with the pad forming one wall.
  • a dressing according to claim 5 which additionally includes pressure applying means for increasing the pressure in the reservoir.
  • a dressing according to claim 5 which additionally includes securing means for attaching the dressing to the skin of the host.
  • a dressing according to claim 9 wherein the pharmacologically active material is a polypeptide.

Abstract

A dressing for administering a drug through the skin of a host comprising a reservoir for the drug and, located between the reservoir and the skin of the host when the dressing is in use, a pad provided with tiny spikes. These tiny spikes augment the absorption of the drug without causing irritation.

Description

United States Paten 1191 Ganderton et al.
1451 June 4, 1974' DRESSING Inventors: David Ganderton; James McAinsh;
Gordon Varney, all of Macclesfield, England Imperial Chemical Industries Limited, London, England Filed: Jan. 24, 1973 Appl. No.: 326,474
Assignee:
[30] Foreign Application Priority Data Feb. 14, 1972 Great Britain 006692/72 US. Cl 128/268, 128/2 W, 128/260,
I 128/253 Int. Cl. A6" 7/02 Field Search 128/2 W, 260, 268, 253,
References Cited 7 UNlTED STATES PATENTS 3/1962 Baron 128/214 F Kravitz et a1. 128/253 3,062,212 1 1/1962 3,072,122 1/1963 Rosenthul 128/253 R25,637 8/1964 Kravitz et al. 128/253 3,167,073 1/1965 Rosenthal 1. 128/253 3,416,530 12/1968 Ness 128/260 3,545,439 12/1970 Duncan... 128/260 3,565,075 2/1971 Jerry 128/268 3,595,231 7/1971 Pistor 128/253 Primary ExtzminerAldrich F. Medbery Attorney, Agent, or Firm-Cushman, Darby & Cushman ABSTRACT A dressing for administering a drug through the skin of a host comprising a reservoir for the drug and, located between the reservoir and the skin of the host when the dressing is in use. a pad provided with tiny spikes. These tiny spikes augment the absorption of the drug without causingirritution- 10 Claims, 2 Drawing Figures PATENTEDJUN 41914 III HHIIIIIIVIIIIIIILLLL IHIH'HHHHIHHII This invention relates to a dressing for application to the skin. In particular, it relatesto a dressing the primary use of which is not toprotect, or apply medication to, a wound or lesion, but in the administration of a pharmacologically active material to man or an animal.
It is well-known that pharmacologically active materials, including drugs and medicinal products, may be administered to man or animals by a variety of routes of which the most important are by mouth, by injection or topically. However, topical application does not usually result in the pharmacologically active material becoming distributed throughout the body'of the host, and not all pharmacologically active materials may be administered by mouth. Injection is an inconvenient method of administration, especially if it has to be done frequently, and there is a need for an alternative.
It is an object of the present invention to provide a dressing which, on application to the skin, will enable a pharmacologically active material to pass from a reservoir through the stratum corneum and be adsorbed sufficiently to become distributed throughout the body of the host. An essential component of this dressing is a pad or plaster, provided with minute spikes, which is located in contact with the skin.
According to the invention therefore there is provided a pad comprising a sheet of material provided with tiny fibres projecting from at least one face of the sheet, the fibres being sufficiently rigid and projecting sufficiently from one face of the sheet such that upon application of that face of the sheet to the skin of a host, the fibres penetrate the skin to permit a liquid formulation of a pharmacologically active material, when present, to pass into the host and become distributed throughout the body of the host.
The inventionthus provides the basis of a dressing which can be used as an alternative to injection for the administration of a pharmacologically active material.
The number of fibres projecting from a unit area of the sheet may vary widely, but in the preferred embodiments, a multitude of fibres are used. Thus, for example, while some patches may have as few as 4 fibres per cm others may have as many as, or more than, 100 fibres per cm depending upon the diameter of the fibres; it being necessary that the fibres be spaced apart sufficiently to penetrate the skin. Usually, the fibres will be made from material different from that of the sheet,-and in such a case, the fibres are necessarily located within the sheet as well as projecting from a face of the sheet. However, the fibres may be made of the same material as the sheet and simply project from the sheet. I
A wide variety of materials, especially plastics materials, are known which may be used to form the sheet.
Particularly useful such materials are, for example,
plasticised or unplasticised homopolymeric thermo plastics, for example polyvinylchloride, polyvinylbutyral, polyethylene, polyamides, for example nylon, or cellulosics such as cellulose acetate; plasticised or unplasticised copolymeric thermoplastics, for example ethylene vinyl acetate; cross-linked water soluble polymers, for example polyvinylacetate or polyvinylpyrrolidone; rubbers, both natural and synthetic, for example polyisobutylene or polybutadiene; or foams, for example polyurethane foam, polyester foam or cellulose foam. In this lattercase, the range of materials which may be used is very wide indeed, but care should be taken to choose a foam which is sufficiently rigid to support the fibres and yet sufficiently porous. Preferred plastics materials for the sheet are cellulose acetate or nylon.
The sheet mayalso be made of metal, for example stainless steel, which may either be provided with fibres in the form of fine stainless steel tubes or projections of metal left round the edges of holes punched in the metal sheet. Alternatively a former, for example a naturally spiky material such as a nettle or delphinium leaf may be coated with a metal to give a pad according to the invention, or-a pad prepared from other materials may be coated with metal to strengthen the fibres.
The fibres may be made of any material the surface of which is inert to body tissue and which is sufficiently strong when in the form of tiny fibres to penetrate the stratum corneum under the conditions in which the complete dressing is used. Particularly suitable such materials are, for example, inorganic materials, for example a glass, carbon, alumina, zirconia or silicon nitride; organic materials, for example nylon or polyparabenzamide; or metals, for example stainless steel. Alternatively, a bio-degradable material may be used. The type of material chosen for any particular use will depend upon the site at which the complete dressing is to be applied,the nature of the drug to be administered and any other features associated with that particular use of the complete dressing.
In a preferred use of the pad, a reservoir of pharmacologically active material is arranged'to dispense that material on to that surface of the pad remote from the projecting fibres. In this use, the pad must be permeable to a liquid formulation of a pharmacologically active material. This permeability may be achieved by using fibres in the form of tiny tubes, usually called capillary tubes, by using a sheet of material provided with a number of transverse holes, or by using an intrinsi of the desired liquid formulation. Any method of combination of methods of rendering the pad permeable may be used depending upon whether solid or hollow fibres are used and whether or not an intrinsically'permeable sheet is used, but the use of hollow fibres is considered to be desirable.
The precise diameter of the fibres is not critical provided that they can penetrate the stratum coneum, but it is preferred that the diameter be in the range 8 pm. to pm. unless the ends of thefibres are sharpened in which case, the diameter of the end of the fibre is preferably in the range 8 am. to 100 am. Thelength of fibre which projects from the sheet is, however, important since it must be longenough to penetrate the stratum corneum, but not be so long that serious irritation is caused. In this context, a penetration of at least 20 ,um. is desirable, and a penetration of 1,000 pm. is probably the maximum which can be tolerated, depending upon the site at which the pad is located. The fibres therefore should project from the sheet for a dis tance within the above range, and for preference; within the range 50-500 um. Clearly, the fibres should be aligned so that they project from that face of the 3 as an angle of approximately 45-90 to the face of the sheet. I
It is envisaged-that any liquid formulation of a pharmacologically active material may be used in conjunction with the pad of the invention provided that the formulation has a sufficiently low viscosity to pass through the pad by the means provided. Not only solutions, but suspensions and creams can be used with the appropriate pad. I
A pad according to the invention may be constructed by any suitable method. Thus for the construction of small pads, the fibres may be laid individually on a work base and cemented together using a solution of a plastics material as defined above to form a sheet con-v taining the fibres. Several such sheets may then be joined to form a block which on being sliced normal to the fibres, produces .a sheet containing transverse fibres. On washing the surface of such a sheet with solvent, the fibres can be exposed to any desired length. Alternatively the fibres may be drawn directly on to a drum coated with plastics material and while still on the drum coated with the sameplastics material to give a sheet similar to that produced by hand. Other techniques are the tack-spin process for producing a carpet-like pile of fibres, modified whereby a micro-mesh grid is usedto draw a plastics material in the molten state into a pad of fibres, orthe flock-spraying process for depositing whiskers of organic or inorganic material upon a plastics backing.
A pad according to the invention can be'used to assist the absorption of a topically applied formulation of a pharmacologically active material, for example a cream or gel, by being placed over the applied formulation. In this case, of course, the pad need not be permeable. However the principal use envisaged for a pad according to the invention is as part of a dressing for the administration of a pharmacologically active material to man or an animal.
According to a further feature of the invention there is provided a dressing for the administration of a pharmacologically active material to a host comprising a pad as previously defined in accordance with the invention in'which the pad is permeable to a liquid formulation of a pharmacologically active material, and a reservoir fora liquid formulation of a pharmacologically active material so located that the pharmacologically active material, when present, can pass from the reservoir and through the pad.
In order that this aspect of the invention may be clearly understood, two simple embodiments of a dressing according to the invention will now be described with reference to the accompanying drawings of which:
FIG. Iis'a diagrammatic representation of a vertical section of one embodiment I and I FIG. II is a diagrammatic representation of a vertical section of another embodiment. I Referring first to FIG. I, the dressing comprises a relatively rigid case I of metal or hard plastics material in the shape of an inverted shallow dish provided with a rim 2. Across the case 1, approximately in line with the rim 2, is a pad according to the invention in the form of a sheet of plastics material 3, provided with tiny fibres 4 projecting from the lower face of the sheet 3. As illustrated, the projection of the fibres 4 from the sheet 3 is much exaggerated in order'to render it visible. Particular pads which may be in the dressing are illustrated in theaccompanying Example 1-6, and in the event of such a pad not being permeable to a formulation of pharmacologically active material by virtue of the permeability of the sheet or the fibres being hollow, the pad is made permeable by being pierced in 5-10 places. If necessary, such intrinsic permeability is augmented by holes pierced through t h e pad. The space formed between the pad and the case 1 forms a reservoir 5, and .at the upper part of case 1 (the base of the inverted dish) is located a means for filling the reservoir in the form of ahole which is closed by a plug 6, made of relatively soft material, for example'neoprene, which is capable of re-sealing after a needle has been passed through and then withdrawn from the plug. Secured to the case 1 are straps 7 which extend from each side of the case 1. v
I In use, the dressing is secured upon the skin of the host to whom a phannacologically active material is to be administeredby means of the straps 7 so'that the fibres 4, projecting from the sheet 3 are held against the surface of the skin. A liquid formulation of the pharmacologically active materiaL'usually in the form of a solution, is filled into the reservoir 5 through the needle of a hypodermic syringe inserted through the plug 6.
When the reservoir 5 is filled,-the' needle is withdrawn and the plug re-seals. The dressing is .then left in place on the skin of the host until sufficient pharmacolog-' the skin of the host. I I
Referring now to FIG. II, the dressing illustrated is ically active material has been administered through similar to that of FIG. I in that it comprises a relatively I rigid case 1, and a pad, formed from a sheet of plastics material 3 with fibres 4, forming a reservoir 5 which can be filled with a liquid formulation of a pharmacologically active material via a plug 6 located in the side wall of the case 1. The dressing of FIG. II is however provided with means for applying pressure to the formulation of pharmacologically active material, when such is present in the reservoir 5, in the form of a chamher 8 in theupper part of the case 1, separated from the reservoir 5 by a flexible membrane'9, and capable of retaining gas under a pressure greater than atmospheric pressure. In the particular embodiment of FIG. II, the chamber 8 can contain granules of sodium bicarbonate, preferably coated with a polymer, so that on admitting an acidic solution to the chamber 8 via the needle of a hypodermic syringe inserted through the plug 10, carbon dioxide gas is slowly generated and a pressure is exerted on the-membrane 9. I
The embodiment of FIG. II is used in the same way as that of FIG. I, being secured to the host by straps 7.
Clearly the two embodiments illustrated represent.
only particular examples of dressings'according to the invention, and many variations of detail can be envisaged.
Thus the reservoir may be distinct from the pad, for example the walls of the reservoir may be separate from the case and/or the pad. The reservoir could be, for example, a sachet of plastics material permeable to the liquid formulation of the pharmacologically active material and located within the space formed by the case and the pad in the embodiments illustrated, or it could be formed from the case and a permeable .wall extending across the case along, the inside of the pad. Alternatively, it could be in the form of, for example,
a foam in which a solution of the pharmacologically active material can beretained by capillary action; a capsule which can be filled with pharmacologically active material to be pierced with a needle when it is desired to admit that material to the pad; or a piece of wadding which may be impregnated with the desired pharmacologically active'material. As yet a further alternative, the reservoir may be a gel which may be impregnated with pharmacologically active material as desired.
When the dressing is provided with pharmacologically active material and is in use, that material will diffuse from the reservoir to the pad, and the rate at which this takes place isdependent upon the nature of the reservoir wall and its thickness, both of which can be varied as desired. In the cases illustrated where the pad itself forms one wall of the reservoir, the rate of diffusion is dependent upon the pad and its fibres.
The dressing may also be provided with a layer of ma terial between the reservoir and the pad to act as a diffusion layer to control the rate of delivery of the pharmacologically-active material to the pad.
As illustrated in FIG. II, the dressing may also be provided with means whereby pressure is exerted on the formulation of pharmacologically active material toincrease the rate at. which it passes from the reservoir and/or through the pad. Alternatives to the specific means illustrated are, for example, a distendible reservoir which can be filled under pressure; a spring-loaded reservoir which exerts a mechanical or hydrostatic pressure on its contents; or a pressure bandage which is used both to retain the dressing in place and to exert pressure on the contents of the reservoir.
In addition, or as an alternative to, a pressure bandage, the dressing may be secured to the skin of a host by means of adhesive tape or an elasticated net, and such securing means may form part of the dressing itself. As part of the securing means of the dressing, in order to prevent undue leakage of the formulation of pharmacologically active material from the periphery of the area of skin to which the pad is pressed, the area surrounding the pad, for example the rim 2 in the embodiments illustrated or partof the straps 7, may bear an adhesive tosecure that area to the skin of the host.
As indicated above, the rate of diffusion of the liquid formulation of pharmacologically active material from the reservoir to the host is dependent upon the nature of the reservoir and the nature of the pad. Clearly, the total amount of material administered to the host is also dependent upon the surface area of the reservoir and pad. When an extremely potent drug is to be administered, a small surface area only is required, and the pad may have an area of only a few cm Forless potent materials, where administration of a larger amount of material is necessary, a greater surface area is needed and the dressing may be large enough," say to cover the whole of a patients forearm or a major part of the abdomen.
It will be clear that a dressing according to the present invention, as well as being capable of being used to administer pharmacologically active materials normally given by injection, can also be used to administer such materials continuously over an extended period. Such amethod of administration enables the variation in the concentration of a pharmacologically active material in the blood of a host, produced by administration of the material at intervals, to be reduced, and this advantage is not limited to materials which are normally administered by injection.
tides, for example polypeptide hormones and synthetic polypeptides possessing some at least of the pharmacological properties of the hormones, for example insulin,
oxytocin, bradykinin, gastrin, pentagastrin or urogastrone; or prostaglandins.
As a further feature of the invention there is provided a dressing as defined together with aliquid formulation of a pharmacologically active material. 7
Pads according to the invention are illustrated by the following Examples, and such pads may be tested for efficacy by comparing the transfer of a solution containing a pharmacologically active material through skin in the presence of the pad with the transfer effected in its absence. Both in vitro and in vivo methods may be used. The following is an example of such a test:
. A pad, prepared as described in Example 2, was applied to a clipped and shaved area on the back of a rabbit and secured in place by a rubber pad containing a 2 cm. diameter hole in register with the prepared area of the pad. One ml. of a solution of C radio labelled 3-t-butylaminol 5-propionamido-naphthl -yloxy )2- propanol, a B-adre'nergic blocking agent. in water containing 0.74 mg./ml. was applied to the pad uniformly over a period of 5 hours. Blood samples were taken at regular intervals from the ear of the rabbit and the amount of radioactive drug present measured using a scintillation counter. The experiment was repeated in the absence of the pad and again with the stratum corneum of the skin removed by a hand dermatome. The following results were obtained:
Peak blood concentration observed Application to:
Skin less than 2-3 ngJml. Pad prepared as in Ex. 2 l4 ngJml. Skin minus straum corneum 48 ng./ml.
These results show that the pad increased the absorption of the pharmacologically active'material through the stratum corneum from an extent giving a negligible peak blood concentration to nearly one third of that obtainable when the stratum corneum was absent.
EXAMPLE 1 Fibres, in the form of glass capillary tubes 40 pm. in external diameter and approximately 15 cm. long, were laid individuallyon a glass plate parallel to each other and about 0.5 mm. apart. The ends of the tubes were retained on two strips of double-sided adhesive tape located approximately 13 cm. apart. A solution in acetone of cellulose acetate containing acetyl triethyl citrate as plasticiser was brushed on to the aligned glass tubes and the solvent allowed to evaporate. The process was repeated until a film 0.5l mm. thick had been built up. Several such films were prepared and cut into squares approximately 2.5 cm. X 2.5 cm. The faces of these squares were then brushed with acetone and laid on top of each other with the tubes all pointing in the same direction. Pressure'was applied to the stack of film for several hours, causing the individual squares of film to adhere together to form a cube. This cube was then sliced with a microtomenormal to the axis of alignment of the tubes to produce small sheets of material about 1-2 mm. thick containing glass capillary tubes arranged at 1 mm. intervals across the thickness of the sheet. One face of a small sheet was then etched away by alternately brushing that surface with acetone and then with water until about 100p.m. of glass capillary tube was exposed projecting from the surface of the sheet.This condition usually took some 30-40 applications of acetone and water to achieve and the extent of projection of the tubes was checked by examination of the sheet under a microscope using oblique illumination. In order to avoid blockage of the capillary tubes, air was blown through the pad during the etching process, and this was conveniently achieved by clamping the pad over the surface of a fine ground glass funnel through which air was being blown.
The product was a square of cellulose actate sheet having a centre portion 2 cm. in diameter provided with tiny glass capillarytubes about 0.5 mm. apart extending through the sheet and projecting from one surface by about 100 um.
I g EXAMPLE 2 q The procedure described in Example 1 was repeated except that solid glass fibres'40 pm. in diameter were a. EXA B E:
A platinum crucible was filled with small spheres of E-glass and the whole heated to l,O C. to melt the glass. The crucible was then maintained at l,200 C. for about 2 hours after which the glass was ready tobe drawn into a fibre on a rotating drum. The drum was first coated with a layer of plastics material, usually cellulose acetate, by application of a solution of the plastics material in acetone to the surface of the drum and evaporation of the'acetone. A fibre of glass was then drawn from the tip of the crucible and wound on to the drum through a guide. The drum was rotated, and the guide'wasallowed to traverse the coated surface of the drum at a speed to give the required density of wound fibre, usually 1 fibre/mm. The fibre was then cut, and a coat of plastics material applied to the wound fibre using asolution in acetone. After the acetone had evaporated, the film of plastics material with the glass fibres aligned within it was stripped from the drum. The operation was repeated many times, and then all the sheets so obtained were then interleaved with sheets of the same. plastics material of the same thickness but not containing glass fibres. The sheets were treated with a small amount of acetone and/or methanol as solvent, and by applying pressure to the sheets, a block was built up in which the glass fibres were all aligned in the same direction and evenly spaced apart. The block was then sectioned transverse to the glass fibres to give small sheets of material about 1-2 mm. thick containing glass fibres at approximately 90 to the plane of the sheet and evenly spaced apart. One surface of the sheet was then etched away using a mixture of acetone and methanol, conveniently 60-70 percent v/v of acetone, to leave the glass fibresprojecting from the surface of the sheet. A particularly convenient technique for etching a numberof such sheets was to secure such sheets to the circumference of a wheel and, by rotation of the Plastics Solid or Diameter Projection of Material Hollow glass of fibre i ibrefrmn fibre plastics sheet Cellulose acetate solid pm. 5a 150 urn. containing acetyl V 140-340 1.1m. triethyl citrate 7 66-180 51 as plasticiser (L300 mp 100-300 pm.
I 80-240 ,tm. 120-340 [.Lf'll. 1 10 pin. ca. 150 um. hollow 40-60 [LIT], Ca. 150 um. nylon* solid 40 gm. 3 @400 m.
wheelQallow the sheets to rub against one or more brushes loaded with solvent.
In this technique, the diameter of the, drawn fibre could be varied by variation in the speed of rotation of the drawing drum. Thus typically, a drawing'speed of 0.5 metre/sec. produced a fibre of about 40 um. diameter, and a drawing speed of 3 metres/sec. produced a fibre of 15 pm. diameter. 0
Also, the extent of projection of the fibre from the surface of the sheet of plastics material could be varied by controlling the extent of the etching of the plastics material. In any particular pad, the fibres did not all project to the same extent, but nevertheless, a variation in average projection from about pm. to 250 ptm., with individual variation from 50 pm. to 400 um. could be achieved. r
In a variation of the above technique, a glass tube of approximately 1 mm. external diameter was drawn through a heater at 800 C. and wound on to a drum coated with plastics material asabove. By following the above general procedure, sheets of plastics material provided with tiny, projecting hollow glass fibres were produced.
By using the techniques described above. a considerable variety of pads'comprising a sheet of plastics material provided with a multitude of tiny glass fibres projecting from one face, thereof have been preparedjA representative selection of such pads is set out below:
* 1n the case of pads made with nylon as the plastics material. the sheets without glass fibres were obtained by compression moulding instead of by evaporation ofa solution. and the pads were etched with methanol.
. j The procedure described in Ex'amp1e l was repeated using hollow nylon fibres of 50 pan. external diameter or carbon fibres of 10 um. diameter to give pads of cellulose acetate provided with tiny hollow nylon or carbon fibres projecting to about 1.5 pun. from the-surface.
. v.1; EKAMBUQ... V. v
A sheet of EN 58B stainless steel. 26 am. in thickness was cut into discs about 1.5 cm. in diameter and 20 holes punched into each disc by means of a sewing needl mounted in the chuck of a bench drill which was lowereii filfoiifirotatiohIiii'tothe steel'disc to a controlled extent. The holes so produced were 78 pm. in diameter and a burr 104 pm. in length was left projecting from one side of the steel sheet. The net result was a pad, consisting of a sheet of steel provided with tiny fibre-like spikes projecting from one surface, and being permeable to liquid by virtue of the holes.
' EXAMPLE 6 the base, each 200 pm. in diameter. Fine steel tubes 200 pm. in external diameter, 100 pm. in internal diameter were sharpened at one end and then cemented into the holes leaving 150 pm. of sharpened tube projecting from the lower face of the base of the dish. The net result was a pad of stainless steel provided with fibre-like sharpened hollow steel tubes projecting from one surface.
What we claim is:
l. A pad for augmenting the absorption of a liquid formulation of a pharmacologically active material through the skin of a host comprising a sheet of material, a plurality of tiny hollow fibres passing through the sheet and projecting from at least one face of said sheet, said fibres having an external diameter at the end of the fibre in the range 8 pm. to 100 um. and projecting from said sheet from 20 pm. to 1,000 ;.m and a means on one side of said sheet material constituting a means for supplying said liquid material.
2. A pad according to claim 1 wherein the sheet is provided with a multitude of said tiny hollow fibres.
3. A pad according to claim 1 wherein the fibres are composed of glass.
4. A pad according to'claim 3 wherein the sheet is made from cellulose acetate.
5. A dressing for administering a liquid formulation of a pharmacologically active material to a host through the skin of said host, comprising a pad according to claim 1 said supply means comprising a reservoir for receiving a liquid formulation of the phannacologically active material located to permit said liquid formulation, when present, to pass from said reservoir and through said pad to the skin of said host.
6. A dressing according to claim 5 wherein the reservoir comprises a case with the pad forming one wall.
7. A dressing according to claim 5 which additionally includes pressure applying means for increasing the pressure in the reservoir.
8. A dressing according to claim 5 which additionally includes securing means for attaching the dressing to the skin of the host.
9. A dressing according to claim 5 wherein the reservoir contains a plug for the insertion of a means for supplying said liquid formulation of the pharmacologically active material.
10. A dressing according to claim 9 wherein the pharmacologically active material is a polypeptide.

Claims (10)

1. A pad for augmenting the absorption of a liquid formulation of a pharmacologically active material through the skin of a host comprising a sheet of material, a plurality of tiny hollow fibres passing through the sheet and projecting from at least one face of said sheet, said fibres having an external diameter at the end of the fibre in the range 8 Mu m. to 100 Mu m. and projecting from said sheet from 20 Mu m. to 1,000 Mu m and a means on one side of said sheet material constituting a means for supplying said liquid material.
2. A pad according to claim 1 wherein the sheet is provided with a multitude of said tiny hollow fibres.
3. A pad according to claim 1 wherein the fibres are composed of glass.
4. A pad according to claim 3 wherein the sheet is made from cellulose acetate.
5. A dressing for administering a liquid formulation of a pharmacologically active material to a host through the skin of said host, comprising a pad according to claim 1 said supply means comprising a reservoir for receiving a liquid formulation of the pharmacologically active material located to permit said liquid formulation, when present, to pass from said reservoir and through said pad to the skin of said host.
6. A dressing according to claim 5 wherein the reservoir comprises a case with the pad forming one wall.
7. A dressing according to claim 5 which additionally includes pressure applying means for increasing the pressure in the reservoir.
8. A dressing according to claim 5 which additionally includes securing means for attaching the dressing to the skin of the host.
9. A dressing according to claim 5 wherein the reservoir contains a plug for the insertion of a means for supplying said liquid formulation of the pharmacologically active material.
10. A dressing according to claim 9 wherein the pharmacologically active material is a polypeptide.
US00326474A 1972-02-14 1973-01-24 Dressing Expired - Lifetime US3814097A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB669272A GB1408925A (en) 1972-02-14 1972-02-14 Medical pad

Publications (1)

Publication Number Publication Date
US3814097A true US3814097A (en) 1974-06-04

Family

ID=9819069

Family Applications (1)

Application Number Title Priority Date Filing Date
US00326474A Expired - Lifetime US3814097A (en) 1972-02-14 1973-01-24 Dressing

Country Status (14)

Country Link
US (1) US3814097A (en)
JP (1) JPS4893192A (en)
AR (1) AR195415A1 (en)
AU (1) AU5145073A (en)
BE (1) BE795384A (en)
BR (1) BR7301058D0 (en)
CH (1) CH560544A5 (en)
DE (1) DE2305989A1 (en)
DK (1) DK131270B (en)
FR (1) FR2172168A1 (en)
GB (1) GB1408925A (en)
LU (1) LU67007A1 (en)
NL (1) NL7301843A (en)
ZA (1) ZA73459B (en)

Cited By (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026290A (en) * 1974-11-30 1977-05-31 Fisons Limited Method of administering medicaments through the skin
US4036229A (en) * 1974-11-06 1977-07-19 Rosolino Marinello Apparatus for assisting the treatment of wounds or inflammations internal to the human body
US4340048A (en) * 1981-03-28 1982-07-20 Alza Corporation Self-driven hypodermic injector
EP0081975A2 (en) * 1981-12-14 1983-06-22 Nicholas H. Maganias Device and method for allergy testing
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4455142A (en) * 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
EP0114125A2 (en) * 1983-01-20 1984-07-25 Almedco, Inc. Medication application systems
US4473083A (en) * 1981-12-14 1984-09-25 Maganias Nicholas H Device and method for allergy testing
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
US4655766A (en) * 1985-08-01 1987-04-07 Alza Corporation Fluid imbibing pump with self-regulating skin patch
US4787888A (en) * 1987-06-01 1988-11-29 University Of Connecticut Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)
US4802493A (en) * 1981-12-14 1989-02-07 Maganias Nicholas H Device and method for allergy testing
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US5000746A (en) * 1987-08-11 1991-03-19 Friedrichsfeld Gmbh Keramik- Und Kunststoffwerke Wound covering having connected discrete elements
US5034386A (en) * 1986-01-31 1991-07-23 Whitby Research, Inc. Methods for administration using 1-substituted azacycloalkanes
US5060642A (en) * 1990-01-05 1991-10-29 Gilman Thomas H Wound dressing with air permeable bacteria impermeable reservoir
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5399683A (en) * 1993-03-26 1995-03-21 Inflazyme Pharmaceuticals, Inc. Mirror amide cord factors and mirror thioester cord factors for diagnosis of tuberculosis
US5423778A (en) * 1989-12-14 1995-06-13 Elof Eriksson System and method for transplantation of cells
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
WO1999029365A1 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
WO1999029364A1 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
WO1999029298A2 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
US5983136A (en) * 1996-09-17 1999-11-09 Deka Products Limited Partnership System for delivery of drugs by transport
US6091975A (en) * 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
EP1086718A1 (en) * 1999-09-22 2001-03-28 Becton Dickinson and Company Method and apparatus for the transdermal administration of a substance
US6219574B1 (en) * 1996-06-18 2001-04-17 Alza Corporation Device and method for enchancing transdermal sampling
WO2001041864A1 (en) 1999-12-10 2001-06-14 Alza Corporation Skin treatment apparatus for sustained transdermal drug delivery
WO2002002179A1 (en) * 2000-06-29 2002-01-10 Becton, Dickinson And Company Microneedle for delivering a substance into the dermis
US20020042589A1 (en) * 2000-10-05 2002-04-11 Thomas Marsoner Medical injection device
WO2002030281A1 (en) 2000-10-13 2002-04-18 Alza Corporation Microblade array impact applicator
WO2002030506A2 (en) 2000-10-12 2002-04-18 Ink Jet Technology Ltd. Transdermal method
WO2002030300A2 (en) 2000-10-13 2002-04-18 Alza Corporation Microprotrusion member retainer for impact applicator
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US20020123675A1 (en) * 2000-10-13 2002-09-05 Trautman Joseph C. Apparatus and method for piercing skin with microprotrusions
US20020128599A1 (en) * 2000-10-26 2002-09-12 Cormier Michel J.N. Transdermal drug delivery devices having coated microprotrusions
US20020132054A1 (en) * 2001-03-16 2002-09-19 Trautman Joseph C. Method and apparatus for coating skin piercing microprojections
US6454755B1 (en) * 1995-05-22 2002-09-24 Silicon Microdevices Method and apparatus for transdermal delivery of compounds utilizing disruption of the epidermis
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
US20020177839A1 (en) * 2001-04-20 2002-11-28 Cormier Michel J. N. Microprojection array having a beneficial agent containing coating
US20020193729A1 (en) * 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
US20020198509A1 (en) * 1999-10-14 2002-12-26 Mikszta John A. Intradermal delivery of vaccines and gene therapeutic agents via microcannula
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
US20030083641A1 (en) * 2001-10-26 2003-05-01 Massachusetts Institute Of Technology Impedance sensor
US6562014B2 (en) 1999-12-16 2003-05-13 Alza Corporation Device and method for enhancing transdermal flux of agents being sampled
US20030135158A1 (en) * 2001-09-21 2003-07-17 Gonnelli Robert R. Gas pressure actuated microneedle arrays, and systems and methods relating to same
US20030187394A1 (en) * 2002-04-02 2003-10-02 Wilkinson Bradley M Method and device for intradermally delivering a substance
US6629949B1 (en) * 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US20040023844A1 (en) * 2002-05-06 2004-02-05 Pettis Ronald J. Method and device for controlling drug pharmacokinetics
US6690959B2 (en) 2000-09-01 2004-02-10 Medtronic, Inc. Skin-mounted electrodes with nano spikes
US20040030276A1 (en) * 1997-09-22 2004-02-12 Flick Bart A. Conductive wound dressings and methods of use
US20040058882A1 (en) * 1995-05-19 2004-03-25 Elof Eriksson Microseeding device for gene delivery by microneedle injection
US20040062813A1 (en) * 2002-06-28 2004-04-01 Cormier Michel J. N. Transdermal drug delivery devices having coated microprotrusions
WO2004030743A2 (en) 2002-09-30 2004-04-15 Alza Corporation Drug delivery device having coated microprojections incorporating vasoconstrictors
US20040082934A1 (en) * 2002-08-30 2004-04-29 Pettis Ronald J. Method of controlling pharmacokinetics of immunomodulatory compounds
US20040081684A1 (en) * 1996-02-19 2004-04-29 Monash University Topical delivery of antifungal agents
US20040096455A1 (en) * 2002-08-08 2004-05-20 Yuh-Fun Maa Transdermal vaccine delivery device having coated microprotrusions
US20040096463A1 (en) * 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20040138610A1 (en) * 2002-12-26 2004-07-15 Michel Cormier Active agent delivery device having composite members
US20040138612A1 (en) * 2002-07-22 2004-07-15 Shermer Charles D. Patch-like infusion device
US20040158202A1 (en) * 2003-02-12 2004-08-12 Soren Jensen Cover
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
US20040175360A1 (en) * 2000-06-29 2004-09-09 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US20040199103A1 (en) * 2002-06-25 2004-10-07 Sung-Yun Kwon Solid solution perforator for drug delivery and other applications
US20040199123A1 (en) * 2003-04-01 2004-10-07 Nielsen Jens Egebjerg Infusion device and an adhesive sheet material and a release liner
US20040236271A1 (en) * 1997-12-10 2004-11-25 Felix Theeuwes Device and method for enhancing transdermal agent flux
US20040265365A1 (en) * 2003-06-30 2004-12-30 Daddona Peter E. Method for coating skin piercing microprojections
US20050010193A1 (en) * 2002-05-06 2005-01-13 Laurent Philippe E. Novel methods for administration of drugs and devices useful thereof
US20050008683A1 (en) * 2000-06-29 2005-01-13 Becton Dickinson And Company Method for delivering interferons to the intradermal compartment
WO2005004842A2 (en) 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
US20050025778A1 (en) * 2003-07-02 2005-02-03 Cormier Michel J.N. Microprojection array immunization patch and method
US20050031676A1 (en) * 2003-08-04 2005-02-10 Wong Patrick S.L. Method and device for enhancing transdermal agent flux
US20050055010A1 (en) * 2002-05-06 2005-03-10 Pettis Ronald J. Method for altering insulin pharmacokinetics
US20050065466A1 (en) * 2003-08-12 2005-03-24 Becton, Dickinson And Company Patch-like infusion device
US20050089554A1 (en) * 2003-10-24 2005-04-28 Cormier Michel J. Apparatus and method for enhancing transdermal drug delivery
US20050089553A1 (en) * 2003-10-28 2005-04-28 Cormier Michel J. Method and apparatus for reducing the incidence of tobacco use
US20050096586A1 (en) * 2003-10-31 2005-05-05 Trautman Joseph C. Self-actuating applicator for microprojection array
WO2005042054A2 (en) 2003-10-24 2005-05-12 Alza Corporation Pretreatment method and system for enhancing transdermal drug delivery
US20050106227A1 (en) * 2003-10-28 2005-05-19 Samuel Zalipsky Delivery of polymer conjugates of therapeutic peptides and proteins via coated microprojections
US20050106209A1 (en) * 2003-11-13 2005-05-19 Mahmoud Ameri Composition and apparatus for transdermal delivery
US20050112135A1 (en) * 2003-11-21 2005-05-26 Cormier Michel J. Ultrasound assisted transdermal vaccine delivery method and system
US20050123507A1 (en) * 2003-06-30 2005-06-09 Mahmoud Ameri Formulations for coated microprojections having controlled solubility
WO2005051476A1 (en) * 2003-11-28 2005-06-09 Acrux Dds Pty Ltd Method and system for rapid transdermal administration
US20050163711A1 (en) * 2003-06-13 2005-07-28 Becton, Dickinson And Company, Inc. Intra-dermal delivery of biologically active agents
US20050226922A1 (en) * 2004-04-13 2005-10-13 Mahmoud Ameri Apparatus and method for transdermal delivery of fentanyl-based agents
US20050240154A1 (en) * 2004-04-21 2005-10-27 Unomedical A/S: Infusion set with patch
US20050251088A1 (en) * 2002-09-16 2005-11-10 Sung-Yun Kwon Solid micro-perforators and methods of use
US20050256499A1 (en) * 2004-03-03 2005-11-17 Pettis Ronald J Methods and devices for improving delivery of a substance to skin
US20050256045A1 (en) * 2004-05-13 2005-11-17 Mahmoud Ameri Apparatus and method for transdermal delivery of parathyroid hormone agents
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
US20050266011A1 (en) * 2004-05-19 2005-12-01 Yuh-Fun Maa Method and formulation for transdermal delivery of immunologically active agents
US20050271684A1 (en) * 2004-04-13 2005-12-08 Trautman Joseph C Apparatus and method for transdermal delivery of multiple vaccines
US20050277887A1 (en) * 2000-05-08 2005-12-15 Joel Douglas Micro infusion drug delivery device
US20060030811A1 (en) * 2004-08-03 2006-02-09 Wong Patrick S Method and device for enhancing transdermal agent flux
US20060034902A1 (en) * 2004-08-10 2006-02-16 Cormier Michel J Microprojection apparatus and system with low infection potential
US20060036209A1 (en) * 2003-11-13 2006-02-16 Janardhanan Subramony System and method for transdermal delivery
US20060040864A1 (en) * 2004-08-19 2006-02-23 Mahmoud Ameri Apparatus and method for transdermal delivery of vascular endothelial growth factors
US20060051403A1 (en) * 2004-09-08 2006-03-09 James Matriano Microprojection array with improved skin adhesion and compliance
US20060058736A1 (en) * 2001-04-27 2006-03-16 Alchas Paul G Novel vaccine
US20060067943A1 (en) * 2004-09-28 2006-03-30 Yuh-Fun Maa Stabilization of alum-adjuvanted immunologically active agents
US20060093658A1 (en) * 2004-10-26 2006-05-04 Gayatri Sathyan Apparatus and method for transdermal delivery of desmopressin
US20060129174A1 (en) * 2000-10-16 2006-06-15 Corium International, Inc. Microstructures for delivering a composition cutaneously to skin
EP1674068A1 (en) 1996-02-19 2006-06-28 Acrux DDS Pty Ltd Dermal penetration enhancers and drug delivery systems involving same
US20060142691A1 (en) * 2000-10-13 2006-06-29 Trautman Joseph C Apparatus and method for piercing skin with microprotrusions
US7087035B2 (en) 1999-12-10 2006-08-08 Alza Corporation Device and method for enhancing skin piercing by microprotrusions
US20060182789A1 (en) * 2005-02-16 2006-08-17 Mahmoud Ameri Apparatus and method for transdermal delivery of epoetin-based agents
US20060186256A1 (en) * 2002-09-02 2006-08-24 Mogensen Lasse W Apparatus for and a method of adjusting the length of an infusion tube
US20060204562A1 (en) * 2005-02-16 2006-09-14 Cormier Michel J Microprojection arrays with improved biocompatibility
US7115112B2 (en) 2002-09-02 2006-10-03 Unomedical A/S Device for subcutaneous administration of a medicament to a patient and tubing for same
US20060253078A1 (en) * 2005-04-25 2006-11-09 Wu Jeffrey M Method of treating skin disorders with stratum corneum piercing device
US20060275170A1 (en) * 2005-06-02 2006-12-07 Mahmoud Ameri Method for terminal sterilization of transdermal delivery devices
US7147623B2 (en) 2002-02-12 2006-12-12 Unomedical A/S Infusion device with needle shield
US20060280645A1 (en) * 2005-06-02 2006-12-14 Scott Sellers Method for terminal sterilization of transdermal delivery devices
US20070009587A1 (en) * 2005-06-21 2007-01-11 Peter Daddona Method and device for coating a continuous strip of microprojection members
US20070071828A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070071740A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Purified amniotic membrane compositions and methods of use
US7214221B2 (en) 2002-03-26 2007-05-08 Becton, Dickinson And Company Multi-stage fluid delivery device and method
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
US20070161964A1 (en) * 2006-01-10 2007-07-12 Yuzhakov Vadim V Microneedle array, patch, and applicator for transdermal drug delivery
US7258680B2 (en) 2002-09-02 2007-08-21 Unomedical A/S Device for subcutaneous administration of a medicament to a patient
US20070237788A1 (en) * 2001-02-23 2007-10-11 Nathalie Garcon Non-live trivalent influenza vaccine for one-dose intradermal delivery
US20070270738A1 (en) * 2005-04-25 2007-11-22 Wu Jeffrey M Method of treating ACNE with stratum corneum piercing patch
US20070293814A1 (en) * 2005-09-12 2007-12-20 Trautman Joseph C Coatable transdermal delivery microprojection assembly
US20070293816A1 (en) * 2006-04-25 2007-12-20 Alza Corporation Microprojection Array Application with Grouped Microprojections for High Drug Loading
US20070299388A1 (en) * 2006-04-25 2007-12-27 Alza Corporation Microprojection array application with multilayered microprojection member for high drug loading
US20080009802A1 (en) * 2005-04-25 2008-01-10 Danilo Lambino Method of treating acne with stratum corneum piercing device
US20080039775A1 (en) * 2006-03-15 2008-02-14 Alza Corporation Apparatus and Method for Transdermal Delivery of Parathyroid Hormone Agents to Prevent or Treat Osteopenia
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
WO2008039218A2 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP1911488A2 (en) 1997-12-11 2008-04-16 Alza Corporation Device for enhancing transdermal agent flux
US20080119773A1 (en) * 1997-09-22 2008-05-22 Argentum International, Llc Multilayer conductive appliance having wound healing and analgesic properties
US20080118465A1 (en) * 2001-04-13 2008-05-22 Pettis Ronald J Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption
US20080125687A1 (en) * 1995-09-05 2008-05-29 Flick A Bartholomew Medical device
US20080125743A1 (en) * 2006-11-28 2008-05-29 Yuzhakov Vadim V Tissue Conforming Microneedle Array and Patch For Transdermal Drug Delivery or Biological Fluid Collection
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US7438926B2 (en) 2000-09-08 2008-10-21 Alza Corporation Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
US20090035446A1 (en) * 2005-09-06 2009-02-05 Theraject, Inc. Solid Solution Perforator Containing Drug Particle and/or Drug-Adsorbed Particles
WO2009035818A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20090155330A1 (en) * 2007-04-16 2009-06-18 Corium International, Inc. Vaccine Delivery via Microneedle Arrays
US7594909B2 (en) 2002-09-02 2009-09-29 Unomedical, A/S Apparatus and method for adjustment of the length of an infusion tubing
US20090286246A1 (en) * 2008-05-07 2009-11-19 Wintherix Llc Methods for Identifying Compounds that Affect Expression of Cancer-Related Protein Isoforms
US7621395B2 (en) 2005-06-28 2009-11-24 Unomedical A/S Packing for infusion set and method of applying an infusion set
US7648494B2 (en) 2004-03-26 2010-01-19 Unomedical A/S Infusion set and injector device for infusion set
US20100028390A1 (en) * 2004-03-24 2010-02-04 Cleary Gary W Transdermal Delivery Device
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US20100068708A1 (en) * 2008-05-07 2010-03-18 Wintherix Llc Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US7802824B2 (en) 2002-11-26 2010-09-28 Unomedical A/S Connecting piece for a tubing
US7867199B2 (en) 2004-12-10 2011-01-11 Unomedical A/S Inserter
US20110006458A1 (en) * 2009-04-24 2011-01-13 Corium International, Inc. Methods for manufacturing microprojection arrays
US20110121486A1 (en) * 2008-05-21 2011-05-26 Sea-Jin Oh Method of manufacturing solid solution peforator patches and uses thereof
WO2011119894A2 (en) 2010-03-24 2011-09-29 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
WO2011139765A2 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011143152A2 (en) 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
US8062250B2 (en) 2004-08-10 2011-11-22 Unomedical A/S Cannula device
WO2011153514A2 (en) 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
US8093444B2 (en) 1997-09-22 2012-01-10 Argentum Medical, Llc Multilayer conductive appliance having wound healing and analgesic properties
USD655807S1 (en) 2005-12-09 2012-03-13 Unomedical A/S Medical device
US8152771B2 (en) 2001-09-27 2012-04-10 Unomedical A/S Injector device for placing a subcutaneous infusion set
WO2012094638A1 (en) 2011-01-07 2012-07-12 Skinmedica, Inc. Melanin modification compositions and methods of use
US8283513B2 (en) 1995-09-05 2012-10-09 Argentum Medical, Llc Multilayer wound dressing
US20130018279A1 (en) * 2009-09-01 2013-01-17 Pathway Genomics "blood sample collection apparatus and kits"
DE102013202928A1 (en) 2012-02-23 2013-08-29 Golden Biotechnology Corporation Methods and compositions for treating cancer metastasis
WO2013148701A1 (en) 2012-03-26 2013-10-03 Golden Biotechnology Corporation Methods and compositions for treating arteriosclerotic vascular diseases
EP2650294A1 (en) 2009-10-12 2013-10-16 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US8617487B2 (en) 2009-03-25 2013-12-31 Venture Lending & Leasing Vi, Inc. Saliva sample collection systems
US8702726B2 (en) 2000-10-16 2014-04-22 Corium International, Inc. Method of exfoliation of skin using closely-packed microstructures
DE102013107024A1 (en) 2011-11-15 2014-05-15 Golden Biotechnology Corporation Methods and compositions for treating, modifying, and managing bone cancer pain
WO2014081675A1 (en) 2012-11-21 2014-05-30 Golden Biotechnology Corporation Methods and compositions for treating neurodegenerative diseases
DE102013107025A1 (en) 2011-12-30 2014-07-03 Golden Biotechnology Corporation METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF DIABETIS
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
WO2014130619A2 (en) 2013-02-20 2014-08-28 Golden Biotechnology Corporation Methods and compositions for treating leukemia
US8821446B2 (en) 2007-01-22 2014-09-02 Corium International, Inc. Applicators for microneedles
US8846740B2 (en) 2011-01-04 2014-09-30 Biological Responsibility, Llc Biotherapeutics for the treatment of infectious diseases
US8945071B2 (en) 2010-09-02 2015-02-03 Becton, Dickinson And Company Self-injection device having needle cover with activation preventer
WO2015017561A1 (en) 2013-07-30 2015-02-05 Zosano Pharma, Inc. Low-profile microneedle patch applicator
US8961469B2 (en) 2009-12-16 2015-02-24 Becton, Dickinson And Company Self-injection device
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9114238B2 (en) 2007-04-16 2015-08-25 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
US9265749B2 (en) 2014-02-10 2016-02-23 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US9273051B2 (en) 2011-12-30 2016-03-01 Pharmacyclics Llc Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2016086063A1 (en) 2014-11-25 2016-06-02 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
DK201400154Y4 (en) * 2013-11-14 2016-11-25 Holtsch Medizinprodukte Gmbh Device for covering a puncture site
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9555187B2 (en) 2009-12-16 2017-01-31 Becton, Dickinson And Company Self-injection device
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US9579461B2 (en) 2009-12-16 2017-02-28 Becton, Dickinson And Company Self-injection device
WO2017040617A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2017096304A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9687641B2 (en) 2010-05-04 2017-06-27 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
US9700522B2 (en) 2007-03-19 2017-07-11 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US9717850B2 (en) 2009-12-16 2017-08-01 Becton, Dickinson And Company Self-injection device
US9758533B2 (en) 2014-04-23 2017-09-12 The Research Foundation For The State University Of New York Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
US9808491B2 (en) 2014-06-03 2017-11-07 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
WO2017197240A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US9833562B2 (en) 2009-12-16 2017-12-05 Becton, Dickinson And Company Self-injection device
EP3251722A1 (en) 2001-04-20 2017-12-06 ALZA Corporation Microprojection array having a beneficial agent containing coating and method of forming the coating thereon
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9962534B2 (en) 2013-03-15 2018-05-08 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US10040821B2 (en) 2012-07-11 2018-08-07 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US10195409B2 (en) 2013-03-15 2019-02-05 Corium International, Inc. Multiple impact microprojection applicators and methods of use
US10195340B2 (en) 2009-12-16 2019-02-05 Becton, Dickinson And Company Self-injection device
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10245422B2 (en) 2013-03-12 2019-04-02 Corium International, Inc. Microprojection applicators and methods of use
US10265267B2 (en) 2016-08-31 2019-04-23 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2019113469A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US10336738B2 (en) 2010-08-27 2019-07-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US10363406B2 (en) 2013-04-26 2019-07-30 Toppan Printing Co., Ltd. Method for producing acicular body
US10369277B2 (en) 2005-09-12 2019-08-06 Unomedical A/S Invisible needle
US10384045B2 (en) 2013-03-15 2019-08-20 Corium, Inc. Microarray with polymer-free microstructures, methods of making, and methods of use
US10384046B2 (en) 2013-03-15 2019-08-20 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
WO2019236957A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
US10561635B2 (en) 2016-10-07 2020-02-18 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US10624843B2 (en) 2014-09-04 2020-04-21 Corium, Inc. Microstructure array, methods of making, and methods of use
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
WO2020190890A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics Inc. Nicorandil derivatives
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
US10835512B2 (en) 2014-02-10 2020-11-17 Respivant Sciences Gmbh Methods of treating respiratory syncytial virus infections
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10857093B2 (en) 2015-06-29 2020-12-08 Corium, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US11052231B2 (en) 2012-12-21 2021-07-06 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
WO2021237068A2 (en) 2020-05-21 2021-11-25 Board Of Regents, The University Of Texas System T cell receptors with vgll1 specificity and uses thereof
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20220152316A1 (en) * 2019-02-25 2022-05-19 Asti Corporation Injection needle
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
US11590265B2 (en) 2015-02-23 2023-02-28 Biotissue Holdings Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
US11707492B2 (en) 2016-01-29 2023-07-25 Biotissue Holdings Inc. Fetal support tissue products and methods of use
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980001139A1 (en) * 1978-12-06 1980-06-12 Svedman Paul Device for treating tissues,for example skin
US4460370A (en) * 1981-10-29 1984-07-17 Almedco, Inc. Trans-dermal medication application cell
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
FR2562800A1 (en) * 1984-04-11 1985-10-18 Fournier Laboratoires Device for percutaneous administration of medicaments
GB2221394B (en) * 1988-08-05 1992-03-04 Eilert Eilertsen An injection device
FI941336A (en) * 1993-03-23 1994-09-24 Diomedes Oy A patch that acts as a dispenser
WO2011002034A1 (en) 2009-07-01 2011-01-06 凸版印刷株式会社 Needle-like material
GB2478363A (en) * 2010-03-05 2011-09-07 Ndm Technologies Ltd Microneedle patch and method of manufacture
JP6119609B2 (en) 2011-10-28 2017-04-26 凸版印刷株式会社 Hollow needle-like body manufacturing method, hollow needle-like body and hollow needle-like body liquid feeding system
JP6277953B2 (en) 2012-02-29 2018-02-14 凸版印刷株式会社 Manufacturing method of needle-shaped body
EP2636424A1 (en) 2012-03-09 2013-09-11 LTS LOHMANN Therapie-Systeme AG Therapeutic system with hollow micro-needles
CN104321106B (en) 2012-06-22 2017-05-24 凸版印刷株式会社 Needle-shaped body and manufacturing method for needle-shaped body
JP6390615B2 (en) 2013-06-03 2018-09-19 凸版印刷株式会社 Manufacturing method of needle-shaped body
EP3006047B1 (en) 2013-06-06 2019-08-07 Toppan Printing Co., Ltd. Needle body
WO2015012252A1 (en) 2013-07-22 2015-01-29 凸版印刷株式会社 Needle-shaped body
CZ308744B6 (en) * 2019-10-02 2021-04-21 Grade Medical s.r.o. Equipment for preparing functionalized carriers for medical use

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25637A (en) * 1859-10-04 Cooking-stove
US3023750A (en) * 1959-03-04 1962-03-06 Howard C Baron Self-generating pressure device for infusion administration systems
US3062212A (en) * 1960-08-08 1962-11-06 Kravitz Harvey Vaccinating devices
US3072122A (en) * 1959-01-15 1963-01-08 Rosenthal Sol Roy Package for transcutaneous injection
US3167073A (en) * 1962-01-16 1965-01-26 Rosenthal Sol Roy Transcutaneous injection device
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3545439A (en) * 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3565075A (en) * 1968-05-02 1971-02-23 Frederick Lonnie Jerry Bandage
US3595231A (en) * 1968-02-20 1971-07-27 A Guerin Soc Device for simultaneously injecting a liquid at a plurality of injection points

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25637A (en) * 1859-10-04 Cooking-stove
US3072122A (en) * 1959-01-15 1963-01-08 Rosenthal Sol Roy Package for transcutaneous injection
US3023750A (en) * 1959-03-04 1962-03-06 Howard C Baron Self-generating pressure device for infusion administration systems
US3062212A (en) * 1960-08-08 1962-11-06 Kravitz Harvey Vaccinating devices
US3167073A (en) * 1962-01-16 1965-01-26 Rosenthal Sol Roy Transcutaneous injection device
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3545439A (en) * 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3595231A (en) * 1968-02-20 1971-07-27 A Guerin Soc Device for simultaneously injecting a liquid at a plurality of injection points
US3565075A (en) * 1968-05-02 1971-02-23 Frederick Lonnie Jerry Bandage

Cited By (485)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036229A (en) * 1974-11-06 1977-07-19 Rosolino Marinello Apparatus for assisting the treatment of wounds or inflammations internal to the human body
US4026290A (en) * 1974-11-30 1977-05-31 Fisons Limited Method of administering medicaments through the skin
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4455142A (en) * 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
US4340048A (en) * 1981-03-28 1982-07-20 Alza Corporation Self-driven hypodermic injector
US4473083A (en) * 1981-12-14 1984-09-25 Maganias Nicholas H Device and method for allergy testing
EP0081975A3 (en) * 1981-12-14 1983-12-28 Nicholas H. Maganias Device and method for allergy testing
US4802493A (en) * 1981-12-14 1989-02-07 Maganias Nicholas H Device and method for allergy testing
EP0081975A2 (en) * 1981-12-14 1983-06-22 Nicholas H. Maganias Device and method for allergy testing
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
EP0114125A2 (en) * 1983-01-20 1984-07-25 Almedco, Inc. Medication application systems
EP0114125A3 (en) * 1983-01-20 1985-05-22 Almedco, Inc. Medication application systems
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US4655766A (en) * 1985-08-01 1987-04-07 Alza Corporation Fluid imbibing pump with self-regulating skin patch
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5034386A (en) * 1986-01-31 1991-07-23 Whitby Research, Inc. Methods for administration using 1-substituted azacycloalkanes
US4787888A (en) * 1987-06-01 1988-11-29 University Of Connecticut Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)
US5000746A (en) * 1987-08-11 1991-03-19 Friedrichsfeld Gmbh Keramik- Und Kunststoffwerke Wound covering having connected discrete elements
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US5423778A (en) * 1989-12-14 1995-06-13 Elof Eriksson System and method for transplantation of cells
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5060642A (en) * 1990-01-05 1991-10-29 Gilman Thomas H Wound dressing with air permeable bacteria impermeable reservoir
US5399683A (en) * 1993-03-26 1995-03-21 Inflazyme Pharmaceuticals, Inc. Mirror amide cord factors and mirror thioester cord factors for diagnosis of tuberculosis
US20040058882A1 (en) * 1995-05-19 2004-03-25 Elof Eriksson Microseeding device for gene delivery by microneedle injection
US7422574B2 (en) 1995-05-19 2008-09-09 Applied Tissue Technologies, Llc Microseeding device for gene delivery by microneedle injection
US6454755B1 (en) * 1995-05-22 2002-09-24 Silicon Microdevices Method and apparatus for transdermal delivery of compounds utilizing disruption of the epidermis
US8283513B2 (en) 1995-09-05 2012-10-09 Argentum Medical, Llc Multilayer wound dressing
US8801681B2 (en) 1995-09-05 2014-08-12 Argentum Medical, Llc Medical device
US20080125687A1 (en) * 1995-09-05 2008-05-29 Flick A Bartholomew Medical device
US8293964B2 (en) 1995-09-05 2012-10-23 Argentum Medical, Llc Multilayer laminate wound dressing
US8118791B2 (en) 1995-09-05 2012-02-21 Argentum Medical, Llc Medical device
US20040081684A1 (en) * 1996-02-19 2004-04-29 Monash University Topical delivery of antifungal agents
US7094422B2 (en) 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
EP1674068A1 (en) 1996-02-19 2006-06-28 Acrux DDS Pty Ltd Dermal penetration enhancers and drug delivery systems involving same
US20070118070A1 (en) * 1996-06-18 2007-05-24 Cormier Michel J Device with anchoring elements for transdermal delivery or sampling of agents
US20020016562A1 (en) * 1996-06-18 2002-02-07 Michel J. N. Cormier Device and method for enhancing transdermal flux of agents being delivered or sampled
US6219574B1 (en) * 1996-06-18 2001-04-17 Alza Corporation Device and method for enchancing transdermal sampling
US7184826B2 (en) 1996-06-18 2007-02-27 Alza Corporation Device and method for enhancing transdermal flux of agents being delivered or sampled
US6537264B1 (en) * 1996-06-18 2003-03-25 Alza Corp Device and method for enhancing transdermal flux of agents being sampled
US5983136A (en) * 1996-09-17 1999-11-09 Deka Products Limited Partnership System for delivery of drugs by transport
US20040030276A1 (en) * 1997-09-22 2004-02-12 Flick Bart A. Conductive wound dressings and methods of use
US8455710B2 (en) 1997-09-22 2013-06-04 Argentum Medical, Llc Conductive wound dressings and methods of use
US8449514B2 (en) * 1997-09-22 2013-05-28 Argentum Medical, Llc Conductive wound dressings and methods of use
US8093444B2 (en) 1997-09-22 2012-01-10 Argentum Medical, Llc Multilayer conductive appliance having wound healing and analgesic properties
US20080064997A1 (en) * 1997-09-22 2008-03-13 Argentum International, Llc. Conductive wound dressings and methods of use
US7989674B2 (en) 1997-09-22 2011-08-02 Argentum Medical, Llc Multilayer conductive appliance having wound healing and analgesic properties
US20080119773A1 (en) * 1997-09-22 2008-05-22 Argentum International, Llc Multilayer conductive appliance having wound healing and analgesic properties
US6918901B1 (en) 1997-12-10 2005-07-19 Felix Theeuwes Device and method for enhancing transdermal agent flux
US20040236271A1 (en) * 1997-12-10 2004-11-25 Felix Theeuwes Device and method for enhancing transdermal agent flux
US6050988A (en) * 1997-12-11 2000-04-18 Alza Corporation Device for enhancing transdermal agent flux
US6083196A (en) * 1997-12-11 2000-07-04 Alza Corporation Device for enhancing transdermal agent flux
EP1911488A2 (en) 1997-12-11 2008-04-16 Alza Corporation Device for enhancing transdermal agent flux
WO1999029365A1 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
WO1999029298A2 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
US6953589B1 (en) 1997-12-11 2005-10-11 Alza Corporation Device for enhancing transdermal agent flux
WO1999029364A1 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
EP1911488A3 (en) * 1997-12-11 2008-12-03 Alza Corporation Device for enhancing transdermal agent flux
US6322808B1 (en) 1997-12-11 2001-11-27 Alza Corporation Device for enhancing transdermal agent flux
US6091975A (en) * 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
US20060047243A1 (en) * 1999-09-22 2006-03-02 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
EP1086718A1 (en) * 1999-09-22 2001-03-28 Becton Dickinson and Company Method and apparatus for the transdermal administration of a substance
US20080287864A1 (en) * 1999-09-22 2008-11-20 Rosenberg Zeil B Method and Apparatus for the Transdermal Administration of a Substance
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
SG92728A1 (en) * 1999-09-22 2002-11-19 Becton Dickinson Co Method and apparatus for the transdermal administration of a substrate
US20050124967A1 (en) * 1999-10-14 2005-06-09 Kaestner Scott A. Method and device for delivery of high molecular weight substances
US20030100885A1 (en) * 1999-10-14 2003-05-29 Pettis Ronald J. Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption
US20040131641A1 (en) * 1999-10-14 2004-07-08 Mikszta John A. Intradermal delivery of vaccines and gene therapeutic agents via microcannula
US7473247B2 (en) 1999-10-14 2009-01-06 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US20020198509A1 (en) * 1999-10-14 2002-12-26 Mikszta John A. Intradermal delivery of vaccines and gene therapeutic agents via microcannula
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
WO2001041864A1 (en) 1999-12-10 2001-06-14 Alza Corporation Skin treatment apparatus for sustained transdermal drug delivery
US7087035B2 (en) 1999-12-10 2006-08-08 Alza Corporation Device and method for enhancing skin piercing by microprotrusions
US6562014B2 (en) 1999-12-16 2003-05-13 Alza Corporation Device and method for enhancing transdermal flux of agents being sampled
US20050277887A1 (en) * 2000-05-08 2005-12-15 Joel Douglas Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) * 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
EP1925333A1 (en) * 2000-06-29 2008-05-28 Becton, Dickinson and Company Intradermal delivery of substances
WO2002002179A1 (en) * 2000-06-29 2002-01-10 Becton, Dickinson And Company Microneedle for delivering a substance into the dermis
US8708994B2 (en) * 2000-06-29 2014-04-29 Becton, Dickinson And Company Method for altering drug pharmacokinetics based on medical delivery platform
US9242052B2 (en) 2000-06-29 2016-01-26 Becton, Dickinson And Company Method for altering drug pharmacokinetics based on medical delivery platform
US20040175360A1 (en) * 2000-06-29 2004-09-09 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US20050096632A1 (en) * 2000-06-29 2005-05-05 Pettis Ronald J. Intradermal delivery of substances
US8986280B2 (en) 2000-06-29 2015-03-24 Becton, Dickinson And Company Intradermal delivery of substances
US20110190725A1 (en) * 2000-06-29 2011-08-04 Becton, Dickinson And Company Method for altering drug pharmacokinetics based on medical delivery platform
US20050096630A1 (en) * 2000-06-29 2005-05-05 Pettis Ronald J. Intradermal delivery of substances
US9005182B2 (en) 2000-06-29 2015-04-14 Becton, Dickinson And Company Intradermal delivery of substances
EP1880743A1 (en) * 2000-06-29 2008-01-23 Becton, Dickinson and Company Microneedle for delivering a substance into the dermis
US20050096631A1 (en) * 2000-06-29 2005-05-05 Pettis Ronald J. Intradermal delivery of substances
US9339613B2 (en) 2000-06-29 2016-05-17 Becton, Dickinson And Company Intradermal delivery of substances
US8998877B2 (en) 2000-06-29 2015-04-07 Becton, Dickinson And Company Intradermal delivery of substances
US20050008683A1 (en) * 2000-06-29 2005-01-13 Becton Dickinson And Company Method for delivering interferons to the intradermal compartment
US6690959B2 (en) 2000-09-01 2004-02-10 Medtronic, Inc. Skin-mounted electrodes with nano spikes
US7438926B2 (en) 2000-09-08 2008-10-21 Alza Corporation Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
US20020042589A1 (en) * 2000-10-05 2002-04-11 Thomas Marsoner Medical injection device
WO2002030506A2 (en) 2000-10-12 2002-04-18 Ink Jet Technology Ltd. Transdermal method
US20060142691A1 (en) * 2000-10-13 2006-06-29 Trautman Joseph C Apparatus and method for piercing skin with microprotrusions
US20020123675A1 (en) * 2000-10-13 2002-09-05 Trautman Joseph C. Apparatus and method for piercing skin with microprotrusions
US20020087182A1 (en) * 2000-10-13 2002-07-04 Trautman Joseph C. Microblade array impact applicator
WO2002030300A2 (en) 2000-10-13 2002-04-18 Alza Corporation Microprotrusion member retainer for impact applicator
US7419481B2 (en) 2000-10-13 2008-09-02 Alza Corporation Apparatus and method for piercing skin with microprotrusions
WO2002030281A1 (en) 2000-10-13 2002-04-18 Alza Corporation Microblade array impact applicator
US20050148926A1 (en) * 2000-10-13 2005-07-07 Trautman Joseph C. Microprotrusion member retainer for impact applicator
US6855131B2 (en) 2000-10-13 2005-02-15 Alza Corporation Microprotrusion member retainer for impact applicator
US20060095061A1 (en) * 2000-10-13 2006-05-04 Trautman Joseph C Microblade array impact applicator
US20050234401A1 (en) * 2000-10-13 2005-10-20 Trautman Joseph C Apparatus and method for piercing skin with microprotrusions
US7131960B2 (en) 2000-10-13 2006-11-07 Alza Corporation Apparatus and method for piercing skin with microprotrusions
US8753318B2 (en) 2000-10-13 2014-06-17 Alza Corporation Microprotrusion member retainer for impact applicator
US9192749B2 (en) 2000-10-13 2015-11-24 Alza Corporation Microblade array impact applicator
US7798987B2 (en) 2000-10-13 2010-09-21 Alza Corporation Apparatus and method for piercing skin with microprotrusions
US8702726B2 (en) 2000-10-16 2014-04-22 Corium International, Inc. Method of exfoliation of skin using closely-packed microstructures
US8216190B2 (en) * 2000-10-16 2012-07-10 Corium International, Inc. Microstructures for delivering a composition cutaneously to skin
US20060129174A1 (en) * 2000-10-16 2006-06-15 Corium International, Inc. Microstructures for delivering a composition cutaneously to skin
WO2002094368A1 (en) * 2000-10-26 2002-11-28 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
EP2085109A3 (en) * 2000-10-26 2009-09-02 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
EP2085109A2 (en) 2000-10-26 2009-08-05 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US7537795B2 (en) 2000-10-26 2009-05-26 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US20020128599A1 (en) * 2000-10-26 2002-09-12 Cormier Michel J.N. Transdermal drug delivery devices having coated microprotrusions
US8663155B2 (en) 2000-10-26 2014-03-04 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US20060200069A1 (en) * 2000-10-26 2006-09-07 Cormier Michel J Transdermal drug delivery devices having coated microprotrusions
US20070237788A1 (en) * 2001-02-23 2007-10-11 Nathalie Garcon Non-live trivalent influenza vaccine for one-dose intradermal delivery
US20040096463A1 (en) * 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
US8557251B2 (en) 2001-02-23 2013-10-15 Glaxosmithkline Biologicals, Sa Non-live trivalent influenza vaccine for one-dose intradermal delivery
US7435299B2 (en) 2001-03-16 2008-10-14 Alza Corporation Method and apparatus for coating skin piercing microprojections
US20020132054A1 (en) * 2001-03-16 2002-09-19 Trautman Joseph C. Method and apparatus for coating skin piercing microprojections
US6855372B2 (en) 2001-03-16 2005-02-15 Alza Corporation Method and apparatus for coating skin piercing microprojections
US20050084604A1 (en) * 2001-03-16 2005-04-21 Trautman Joseph C. Method and apparatus for coating skin piercing microprojections
US20080118465A1 (en) * 2001-04-13 2008-05-22 Pettis Ronald J Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption
EP3251722A1 (en) 2001-04-20 2017-12-06 ALZA Corporation Microprojection array having a beneficial agent containing coating and method of forming the coating thereon
US20090143724A1 (en) * 2001-04-20 2009-06-04 Alza Corporation Microprojection Array Immunization Patch and Method
US7963935B2 (en) 2001-04-20 2011-06-21 Alza Corporation Microprojection array having a beneficial agent containing coating
US20020177839A1 (en) * 2001-04-20 2002-11-28 Cormier Michel J. N. Microprojection array having a beneficial agent containing coating
US20060074377A1 (en) * 2001-04-20 2006-04-06 Cormier Michel J Microprojection array immunization patch and method
US20020193729A1 (en) * 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
US20060058736A1 (en) * 2001-04-27 2006-03-16 Alchas Paul G Novel vaccine
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
US20080138286A1 (en) * 2001-06-29 2008-06-12 Pettis Ronald J Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption
US20080118507A1 (en) * 2001-06-29 2008-05-22 Pettis Ronald J Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption
US20040028707A1 (en) * 2001-06-29 2004-02-12 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
US20080119392A1 (en) * 2001-06-29 2008-05-22 Pettis Ronald J Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption
US8920375B2 (en) * 2001-09-21 2014-12-30 Valeritas, Inc. Gas pressure actuated microneedle arrays, and systems and methods relating to same
US20030135158A1 (en) * 2001-09-21 2003-07-17 Gonnelli Robert R. Gas pressure actuated microneedle arrays, and systems and methods relating to same
US8162892B2 (en) 2001-09-27 2012-04-24 Unomedical A/S Injector device for placing a subcutaneous infusion set
US8172805B2 (en) 2001-09-27 2012-05-08 Unomedical A/S Injector device for placing a subcutaneous infusion set
US8152771B2 (en) 2001-09-27 2012-04-10 Unomedical A/S Injector device for placing a subcutaneous infusion set
US20080319392A1 (en) * 2001-10-26 2008-12-25 Angel Aimee B Microneedle transport device
US7364568B2 (en) 2001-10-26 2008-04-29 Massachusetts Institute Of Technology Microneedle transdermal transport device
US20030083619A1 (en) * 2001-10-26 2003-05-01 Massachusetts Institute Of Technology Microneedle transdermal transport device
US7429258B2 (en) 2001-10-26 2008-09-30 Massachusetts Institute Of Technology Microneedle transport device
US7066922B2 (en) 2001-10-26 2006-06-27 Massachusetts Institute Of Technology Transdermal transport device with suction
US20080281273A1 (en) * 2001-10-26 2008-11-13 Massachusetts Institute Of Technology Microneedle transdermal transport device
US7651475B2 (en) 2001-10-26 2010-01-26 Massachusetts Institute Of Technology Microneedle transport device
US20030083618A1 (en) * 2001-10-26 2003-05-01 Massachusetts Institute Of Technology Transdermal transport device with an electrolytic actuator
US20030139727A1 (en) * 2001-10-26 2003-07-24 Massachusetts Institute Of Technology Transdermal transport device with suction
US7645263B2 (en) 2001-10-26 2010-01-12 Massachusetts Institute Of Technology Impedance sensor
US8246582B2 (en) 2001-10-26 2012-08-21 Massachusetts Institute Of Technology Microneedle transdermal transport device
US20030083645A1 (en) * 2001-10-26 2003-05-01 Massachusetts Institute Of Technology Microneedle transport device
US20030083641A1 (en) * 2001-10-26 2003-05-01 Massachusetts Institute Of Technology Impedance sensor
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US7147623B2 (en) 2002-02-12 2006-12-12 Unomedical A/S Infusion device with needle shield
US7214221B2 (en) 2002-03-26 2007-05-08 Becton, Dickinson And Company Multi-stage fluid delivery device and method
EP3167929A1 (en) * 2002-04-02 2017-05-17 Becton, Dickinson and Company Device for intradermally delivering a substance
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US7410476B2 (en) * 2002-04-02 2008-08-12 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20050245877A1 (en) * 2002-04-02 2005-11-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
US20030187394A1 (en) * 2002-04-02 2003-10-02 Wilkinson Bradley M Method and device for intradermally delivering a substance
US7896837B2 (en) * 2002-04-02 2011-03-01 Becton, Dickinson And Company Method and device for intradermally delivering a substance
WO2003084598A1 (en) * 2002-04-02 2003-10-16 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080287871A1 (en) * 2002-04-02 2008-11-20 Wilkinson Bradley M Method and Device for Intradermally Delivering a Substance
US9192750B2 (en) 2002-05-06 2015-11-24 Becton, Dickinson And Company Method and device for controlling drug pharmacokinetics
US7722595B2 (en) 2002-05-06 2010-05-25 Becton, Dickinson And Company Method and device for controlling drug pharmacokinetics
US20040023844A1 (en) * 2002-05-06 2004-02-05 Pettis Ronald J. Method and device for controlling drug pharmacokinetics
US20050055010A1 (en) * 2002-05-06 2005-03-10 Pettis Ronald J. Method for altering insulin pharmacokinetics
US20060264886A9 (en) * 2002-05-06 2006-11-23 Pettis Ronald J Method for altering insulin pharmacokinetics
US20050010193A1 (en) * 2002-05-06 2005-01-13 Laurent Philippe E. Novel methods for administration of drugs and devices useful thereof
US20100262120A1 (en) * 2002-05-06 2010-10-14 Becton, Dickinson And Company Method and device for controlling drug pharmacokinetics
US10322272B2 (en) 2002-05-06 2019-06-18 Becton, Dickinson And Company Method and device for controlling drug pharmacokinetics
US20060074376A1 (en) * 2002-06-25 2006-04-06 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US20040199103A1 (en) * 2002-06-25 2004-10-07 Sung-Yun Kwon Solid solution perforator for drug delivery and other applications
US7182747B2 (en) 2002-06-25 2007-02-27 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US7211062B2 (en) 2002-06-25 2007-05-01 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US20040062813A1 (en) * 2002-06-28 2004-04-01 Cormier Michel J. N. Transdermal drug delivery devices having coated microprotrusions
US20040138612A1 (en) * 2002-07-22 2004-07-15 Shermer Charles D. Patch-like infusion device
US7250037B2 (en) 2002-07-22 2007-07-31 Becton, Dickinson And Company Patch-like infusion device
US7678079B2 (en) 2002-07-22 2010-03-16 Becton, Dickinson And Company Patch-like infusion device
US20040096455A1 (en) * 2002-08-08 2004-05-20 Yuh-Fun Maa Transdermal vaccine delivery device having coated microprotrusions
US20070134719A1 (en) * 2002-08-30 2007-06-14 Becton, Dickinson And Company Method of controlling pharmacokinetics of immunomodulatory compounds
US20040082934A1 (en) * 2002-08-30 2004-04-29 Pettis Ronald J. Method of controlling pharmacokinetics of immunomodulatory compounds
US7594909B2 (en) 2002-09-02 2009-09-29 Unomedical, A/S Apparatus and method for adjustment of the length of an infusion tubing
US7258680B2 (en) 2002-09-02 2007-08-21 Unomedical A/S Device for subcutaneous administration of a medicament to a patient
US7115112B2 (en) 2002-09-02 2006-10-03 Unomedical A/S Device for subcutaneous administration of a medicament to a patient and tubing for same
US7654484B2 (en) 2002-09-02 2010-02-02 Unomedical A/S Apparatus for and a method of adjusting the length of an infusion tube
US20060186256A1 (en) * 2002-09-02 2006-08-24 Mogensen Lasse W Apparatus for and a method of adjusting the length of an infusion tube
US20050251088A1 (en) * 2002-09-16 2005-11-10 Sung-Yun Kwon Solid micro-perforators and methods of use
US8062573B2 (en) 2002-09-16 2011-11-22 Theraject, Inc. Solid micro-perforators and methods of use
WO2004030743A2 (en) 2002-09-30 2004-04-15 Alza Corporation Drug delivery device having coated microprojections incorporating vasoconstrictors
US20040115167A1 (en) * 2002-09-30 2004-06-17 Michel Cormier Drug delivery device and method having coated microprojections incorporating vasoconstrictors
US7802824B2 (en) 2002-11-26 2010-09-28 Unomedical A/S Connecting piece for a tubing
WO2004060473A2 (en) 2002-12-26 2004-07-22 Alza Corporation Active agent delivery device having composite members
US20040138610A1 (en) * 2002-12-26 2004-07-15 Michel Cormier Active agent delivery device having composite members
US20040158202A1 (en) * 2003-02-12 2004-08-12 Soren Jensen Cover
US7481794B2 (en) 2003-02-12 2009-01-27 Unomedical A/S Cover
US7070580B2 (en) 2003-04-01 2006-07-04 Unomedical A/S Infusion device and an adhesive sheet material and a release liner
US20040199123A1 (en) * 2003-04-01 2004-10-07 Nielsen Jens Egebjerg Infusion device and an adhesive sheet material and a release liner
US20050163711A1 (en) * 2003-06-13 2005-07-28 Becton, Dickinson And Company, Inc. Intra-dermal delivery of biologically active agents
US20050123507A1 (en) * 2003-06-30 2005-06-09 Mahmoud Ameri Formulations for coated microprojections having controlled solubility
US7579013B2 (en) 2003-06-30 2009-08-25 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
US20040265365A1 (en) * 2003-06-30 2004-12-30 Daddona Peter E. Method for coating skin piercing microprojections
WO2005004842A2 (en) 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
US20050025778A1 (en) * 2003-07-02 2005-02-03 Cormier Michel J.N. Microprojection array immunization patch and method
US10589023B2 (en) 2003-07-22 2020-03-17 Becton, Dickinson And Company Patch-like infusion device
US8512287B2 (en) 2003-07-22 2013-08-20 Becton, Dickinson And Company Patch-like infusion device
US9597450B2 (en) 2003-07-22 2017-03-21 Becton, Dickinson And Company Patch-like infusion device
US20050065472A1 (en) * 2003-07-22 2005-03-24 Cindrich Chris N. Patch-like infusion device
US9999724B2 (en) 2003-07-22 2018-06-19 Becton, Dickinson And Company Patch-like infusion device
US9364606B2 (en) 2003-07-22 2016-06-14 Becton, Dickinson And Company Patch-like infusion device
US20050031676A1 (en) * 2003-08-04 2005-02-10 Wong Patrick S.L. Method and device for enhancing transdermal agent flux
US8444604B2 (en) 2003-08-12 2013-05-21 Becton, Dickinson And Company Patch-like infusion device
US20050065466A1 (en) * 2003-08-12 2005-03-24 Becton, Dickinson And Company Patch-like infusion device
US20080215015A1 (en) * 2003-08-12 2008-09-04 Chris Cindrich Patch-Like Infusion Device
US7857131B2 (en) 2003-08-12 2010-12-28 Becton, Dickinson And Company Patch-like infusion device
WO2005042054A2 (en) 2003-10-24 2005-05-12 Alza Corporation Pretreatment method and system for enhancing transdermal drug delivery
US20050106226A1 (en) * 2003-10-24 2005-05-19 Cormier Michel J. Pretreatment method and system for enhancing transdermal drug delivery
US20050089554A1 (en) * 2003-10-24 2005-04-28 Cormier Michel J. Apparatus and method for enhancing transdermal drug delivery
US7455654B2 (en) 2003-10-28 2008-11-25 Alza Corporation Method and apparatus for reducing the incidence of tobacco use
US20050106227A1 (en) * 2003-10-28 2005-05-19 Samuel Zalipsky Delivery of polymer conjugates of therapeutic peptides and proteins via coated microprojections
US20050089553A1 (en) * 2003-10-28 2005-04-28 Cormier Michel J. Method and apparatus for reducing the incidence of tobacco use
US20050096586A1 (en) * 2003-10-31 2005-05-05 Trautman Joseph C. Self-actuating applicator for microprojection array
US20070027427A1 (en) * 2003-10-31 2007-02-01 Trautman Joseph C Self-actuating applicator for microprojection array
US7097631B2 (en) 2003-10-31 2006-08-29 Alza Corporation Self-actuating applicator for microprojection array
US9421351B2 (en) 2003-10-31 2016-08-23 Alza Corporation Self-actuating applicator for microprojection array
US20050106209A1 (en) * 2003-11-13 2005-05-19 Mahmoud Ameri Composition and apparatus for transdermal delivery
US20060036209A1 (en) * 2003-11-13 2006-02-16 Janardhanan Subramony System and method for transdermal delivery
US20050112135A1 (en) * 2003-11-21 2005-05-26 Cormier Michel J. Ultrasound assisted transdermal vaccine delivery method and system
WO2005051476A1 (en) * 2003-11-28 2005-06-09 Acrux Dds Pty Ltd Method and system for rapid transdermal administration
US20080226699A1 (en) * 2003-11-28 2008-09-18 Acrux Dds Pty Ltd Method and System for Rapid Transdermal Administration
US20050256499A1 (en) * 2004-03-03 2005-11-17 Pettis Ronald J Methods and devices for improving delivery of a substance to skin
US20100028390A1 (en) * 2004-03-24 2010-02-04 Cleary Gary W Transdermal Delivery Device
US7914480B2 (en) 2004-03-24 2011-03-29 Corium International, Inc. Transdermal delivery device
US8221355B2 (en) 2004-03-26 2012-07-17 Unomedical A/S Injection device for infusion set
US7648494B2 (en) 2004-03-26 2010-01-19 Unomedical A/S Infusion set and injector device for infusion set
US20050271684A1 (en) * 2004-04-13 2005-12-08 Trautman Joseph C Apparatus and method for transdermal delivery of multiple vaccines
US20050226922A1 (en) * 2004-04-13 2005-10-13 Mahmoud Ameri Apparatus and method for transdermal delivery of fentanyl-based agents
US20050240154A1 (en) * 2004-04-21 2005-10-27 Unomedical A/S: Infusion set with patch
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
US20050256045A1 (en) * 2004-05-13 2005-11-17 Mahmoud Ameri Apparatus and method for transdermal delivery of parathyroid hormone agents
US8361022B2 (en) 2004-05-13 2013-01-29 Alza Corporation Apparatus for transdermal delivery of parathyroid hormone agents
US7556821B2 (en) 2004-05-13 2009-07-07 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US20050266011A1 (en) * 2004-05-19 2005-12-01 Yuh-Fun Maa Method and formulation for transdermal delivery of immunologically active agents
US20060030811A1 (en) * 2004-08-03 2006-02-09 Wong Patrick S Method and device for enhancing transdermal agent flux
US20060034902A1 (en) * 2004-08-10 2006-02-16 Cormier Michel J Microprojection apparatus and system with low infection potential
US8062250B2 (en) 2004-08-10 2011-11-22 Unomedical A/S Cannula device
US20060040864A1 (en) * 2004-08-19 2006-02-23 Mahmoud Ameri Apparatus and method for transdermal delivery of vascular endothelial growth factors
US20060051403A1 (en) * 2004-09-08 2006-03-09 James Matriano Microprojection array with improved skin adhesion and compliance
US20060067943A1 (en) * 2004-09-28 2006-03-30 Yuh-Fun Maa Stabilization of alum-adjuvanted immunologically active agents
US20060093658A1 (en) * 2004-10-26 2006-05-04 Gayatri Sathyan Apparatus and method for transdermal delivery of desmopressin
US7867199B2 (en) 2004-12-10 2011-01-11 Unomedical A/S Inserter
US7867200B2 (en) 2004-12-10 2011-01-11 Unomedical A/S Inserter
US20060204562A1 (en) * 2005-02-16 2006-09-14 Cormier Michel J Microprojection arrays with improved biocompatibility
US20060182789A1 (en) * 2005-02-16 2006-08-17 Mahmoud Ameri Apparatus and method for transdermal delivery of epoetin-based agents
US20060253079A1 (en) * 2005-04-25 2006-11-09 Mcdonough Justin Stratum corneum piercing device
US20080009802A1 (en) * 2005-04-25 2008-01-10 Danilo Lambino Method of treating acne with stratum corneum piercing device
US20070049901A1 (en) * 2005-04-25 2007-03-01 Wu Jeffrey M Method of treating acne with stratum corneum piercing device
US20060253078A1 (en) * 2005-04-25 2006-11-09 Wu Jeffrey M Method of treating skin disorders with stratum corneum piercing device
US20070270738A1 (en) * 2005-04-25 2007-11-22 Wu Jeffrey M Method of treating ACNE with stratum corneum piercing patch
US20060275170A1 (en) * 2005-06-02 2006-12-07 Mahmoud Ameri Method for terminal sterilization of transdermal delivery devices
US20060280645A1 (en) * 2005-06-02 2006-12-14 Scott Sellers Method for terminal sterilization of transdermal delivery devices
US20070009587A1 (en) * 2005-06-21 2007-01-11 Peter Daddona Method and device for coating a continuous strip of microprojection members
US7621395B2 (en) 2005-06-28 2009-11-24 Unomedical A/S Packing for infusion set and method of applying an infusion set
US20090035446A1 (en) * 2005-09-06 2009-02-05 Theraject, Inc. Solid Solution Perforator Containing Drug Particle and/or Drug-Adsorbed Particles
US20070293814A1 (en) * 2005-09-12 2007-12-20 Trautman Joseph C Coatable transdermal delivery microprojection assembly
US10369277B2 (en) 2005-09-12 2019-08-06 Unomedical A/S Invisible needle
US20070071828A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US9161954B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8182841B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US9161956B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US9750771B2 (en) 2005-09-27 2017-09-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US20070071740A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Purified amniotic membrane compositions and methods of use
US8440235B2 (en) 2005-09-27 2013-05-14 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9750772B2 (en) 2005-09-27 2017-09-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8153162B2 (en) 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US10632155B2 (en) 2005-09-27 2020-04-28 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US20070231401A1 (en) * 2005-09-27 2007-10-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8420126B2 (en) 2005-09-27 2013-04-16 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP2664337A1 (en) 2005-09-27 2013-11-20 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US20080299087A1 (en) * 2005-09-27 2008-12-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9198939B2 (en) 2005-09-27 2015-12-01 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US9161955B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8460714B2 (en) 2005-09-27 2013-06-11 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US9724370B2 (en) 2005-09-27 2017-08-08 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8455009B2 (en) 2005-09-27 2013-06-04 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US10272119B2 (en) 2005-09-27 2019-04-30 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9956252B2 (en) 2005-09-27 2018-05-01 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
USD655807S1 (en) 2005-12-09 2012-03-13 Unomedical A/S Medical device
USD682415S1 (en) 2005-12-09 2013-05-14 Unomedical A/S Medical device
US20100130940A1 (en) * 2006-01-10 2010-05-27 Yuzhakov Vadim V Method of making microneedle array and device for applying microneedle array to skin
US7658728B2 (en) 2006-01-10 2010-02-09 Yuzhakov Vadim V Microneedle array, patch, and applicator for transdermal drug delivery
US8414548B2 (en) 2006-01-10 2013-04-09 Vadim V. Yuzhakov Method of making microneedle array and device for applying microneedle array to skin
US20070161964A1 (en) * 2006-01-10 2007-07-12 Yuzhakov Vadim V Microneedle array, patch, and applicator for transdermal drug delivery
US20080039775A1 (en) * 2006-03-15 2008-02-14 Alza Corporation Apparatus and Method for Transdermal Delivery of Parathyroid Hormone Agents to Prevent or Treat Osteopenia
US20070293816A1 (en) * 2006-04-25 2007-12-20 Alza Corporation Microprojection Array Application with Grouped Microprojections for High Drug Loading
US20070299388A1 (en) * 2006-04-25 2007-12-27 Alza Corporation Microprojection array application with multilayered microprojection member for high drug loading
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
EP2201840A1 (en) 2006-09-22 2010-06-30 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
WO2008039218A2 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526934A2 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526933A2 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2530083A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2443929A1 (en) 2006-09-22 2012-04-25 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2532234A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2529621A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526771A1 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2529622A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US7785301B2 (en) 2006-11-28 2010-08-31 Vadim V Yuzhakov Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection
US20080125743A1 (en) * 2006-11-28 2008-05-29 Yuzhakov Vadim V Tissue Conforming Microneedle Array and Patch For Transdermal Drug Delivery or Biological Fluid Collection
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US20100305473A1 (en) * 2006-11-28 2010-12-02 Yuzhakov Vadim V Tissue conforming microneedle device for drug delivery or biological fluid collection
US8821446B2 (en) 2007-01-22 2014-09-02 Corium International, Inc. Applicators for microneedles
US9700522B2 (en) 2007-03-19 2017-07-11 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US10238848B2 (en) 2007-04-16 2019-03-26 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
US20090155330A1 (en) * 2007-04-16 2009-06-18 Corium International, Inc. Vaccine Delivery via Microneedle Arrays
US9498524B2 (en) 2007-04-16 2016-11-22 Corium International, Inc. Method of vaccine delivery via microneedle arrays
US9452280B2 (en) 2007-04-16 2016-09-27 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
US9114238B2 (en) 2007-04-16 2015-08-25 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
US8911749B2 (en) 2007-04-16 2014-12-16 Corium International, Inc. Vaccine delivery via microneedle arrays
WO2009035818A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20100068708A1 (en) * 2008-05-07 2010-03-18 Wintherix Llc Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells
US20090286246A1 (en) * 2008-05-07 2009-11-19 Wintherix Llc Methods for Identifying Compounds that Affect Expression of Cancer-Related Protein Isoforms
US20110121486A1 (en) * 2008-05-21 2011-05-26 Sea-Jin Oh Method of manufacturing solid solution peforator patches and uses thereof
US9381680B2 (en) 2008-05-21 2016-07-05 Theraject, Inc. Method of manufacturing solid solution perforator patches and uses thereof
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US8617487B2 (en) 2009-03-25 2013-12-31 Venture Lending & Leasing Vi, Inc. Saliva sample collection systems
US8932539B2 (en) 2009-03-25 2015-01-13 Pathway Genomics Corporation Saliva sample collection systems
US20110006458A1 (en) * 2009-04-24 2011-01-13 Corium International, Inc. Methods for manufacturing microprojection arrays
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US20130018279A1 (en) * 2009-09-01 2013-01-17 Pathway Genomics "blood sample collection apparatus and kits"
EP2650294A1 (en) 2009-10-12 2013-10-16 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US9919097B2 (en) 2009-12-16 2018-03-20 Becton, Dickinson And Company Self-injection device
US10195340B2 (en) 2009-12-16 2019-02-05 Becton, Dickinson And Company Self-injection device
US8961469B2 (en) 2009-12-16 2015-02-24 Becton, Dickinson And Company Self-injection device
US9579461B2 (en) 2009-12-16 2017-02-28 Becton, Dickinson And Company Self-injection device
US9717850B2 (en) 2009-12-16 2017-08-01 Becton, Dickinson And Company Self-injection device
US9555187B2 (en) 2009-12-16 2017-01-31 Becton, Dickinson And Company Self-injection device
US11007316B2 (en) 2009-12-16 2021-05-18 Becton, Dickinson And Company Self-injection device
US9833562B2 (en) 2009-12-16 2017-12-05 Becton, Dickinson And Company Self-injection device
US10967123B2 (en) 2009-12-16 2021-04-06 Becton, Dickinson And Company Self-injection device
US10420881B2 (en) 2009-12-16 2019-09-24 Becton, Dickinson And Company Self-injection device
US10357610B2 (en) 2009-12-16 2019-07-23 Becton, Dickinson And Company Self-injection device
US10080846B2 (en) 2009-12-16 2018-09-25 Becton, Dickinson And Company Self-injection device
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
US10214513B2 (en) 2010-03-24 2019-02-26 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
US8957216B2 (en) 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2011119894A2 (en) 2010-03-24 2011-09-29 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
US9212151B2 (en) 2010-03-24 2015-12-15 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
US11607407B2 (en) 2010-04-13 2023-03-21 Relmada Therapeutics, Inc. Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011139765A2 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
US11419816B2 (en) 2010-05-04 2022-08-23 Corium, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
US9687641B2 (en) 2010-05-04 2017-06-27 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
WO2011143152A2 (en) 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
WO2011153514A2 (en) 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
US10336738B2 (en) 2010-08-27 2019-07-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8945071B2 (en) 2010-09-02 2015-02-03 Becton, Dickinson And Company Self-injection device having needle cover with activation preventer
US9675752B2 (en) 2010-09-02 2017-06-13 Becton, Dickinson And Company Self-injection device having needle cover with activation preventer
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
US9550822B2 (en) 2010-10-25 2017-01-24 Questcor Pharmaceuticals, Inc. ACTH prophylactic treatment of renal disorders
US10286041B2 (en) 2010-10-25 2019-05-14 Mallinckrodt Ard Ip Limited ACTH prophylactic treatment of renal disorders
US9254330B2 (en) 2011-01-04 2016-02-09 Biological Responsibility, Llc Biotherapeutics for the treatment of infectious diseases
US8846740B2 (en) 2011-01-04 2014-09-30 Biological Responsibility, Llc Biotherapeutics for the treatment of infectious diseases
US8778315B2 (en) 2011-01-07 2014-07-15 Allergan, Inc. Melanin modification compositions and methods of use
WO2012094638A1 (en) 2011-01-07 2012-07-12 Skinmedica, Inc. Melanin modification compositions and methods of use
US9044404B2 (en) 2011-01-07 2015-06-02 Allergan, Inc. Melanin modification compositions and methods of use
US8236288B2 (en) 2011-01-07 2012-08-07 Skinmedica, Inc. Melanin modification compositions and methods of use
US9675733B2 (en) 2011-04-28 2017-06-13 Tissuetech, Inc. Methods of modulating bone remodeling
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US10426731B2 (en) 2011-06-10 2019-10-01 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
DE102013107024A1 (en) 2011-11-15 2014-05-15 Golden Biotechnology Corporation Methods and compositions for treating, modifying, and managing bone cancer pain
US9273051B2 (en) 2011-12-30 2016-03-01 Pharmacyclics Llc Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DE102013107025A1 (en) 2011-12-30 2014-07-03 Golden Biotechnology Corporation METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF DIABETIS
DE102013202928A1 (en) 2012-02-23 2013-08-29 Golden Biotechnology Corporation Methods and compositions for treating cancer metastasis
WO2013148701A1 (en) 2012-03-26 2013-10-03 Golden Biotechnology Corporation Methods and compositions for treating arteriosclerotic vascular diseases
US10040821B2 (en) 2012-07-11 2018-08-07 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US10253065B2 (en) 2012-07-11 2019-04-09 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US11518782B2 (en) 2012-07-11 2022-12-06 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US10717763B2 (en) 2012-07-11 2020-07-21 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014081675A1 (en) 2012-11-21 2014-05-30 Golden Biotechnology Corporation Methods and compositions for treating neurodegenerative diseases
US11052231B2 (en) 2012-12-21 2021-07-06 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
WO2014130619A2 (en) 2013-02-20 2014-08-28 Golden Biotechnology Corporation Methods and compositions for treating leukemia
US11110259B2 (en) 2013-03-12 2021-09-07 Corium, Inc. Microprojection applicators and methods of use
US10245422B2 (en) 2013-03-12 2019-04-02 Corium International, Inc. Microprojection applicators and methods of use
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
US10195409B2 (en) 2013-03-15 2019-02-05 Corium International, Inc. Multiple impact microprojection applicators and methods of use
US11565097B2 (en) 2013-03-15 2023-01-31 Corium Pharma Solutions, Inc. Microarray for delivery of therapeutic agent and methods of use
US10384045B2 (en) 2013-03-15 2019-08-20 Corium, Inc. Microarray with polymer-free microstructures, methods of making, and methods of use
US10384046B2 (en) 2013-03-15 2019-08-20 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
US9962534B2 (en) 2013-03-15 2018-05-08 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US10363406B2 (en) 2013-04-26 2019-07-30 Toppan Printing Co., Ltd. Method for producing acicular body
WO2015017561A1 (en) 2013-07-30 2015-02-05 Zosano Pharma, Inc. Low-profile microneedle patch applicator
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
DK201400154Y4 (en) * 2013-11-14 2016-11-25 Holtsch Medizinprodukte Gmbh Device for covering a puncture site
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9968586B2 (en) 2014-02-10 2018-05-15 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
EP3653207A1 (en) 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
US10835512B2 (en) 2014-02-10 2020-11-17 Respivant Sciences Gmbh Methods of treating respiratory syncytial virus infections
US9707206B2 (en) 2014-02-10 2017-07-18 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9265749B2 (en) 2014-02-10 2016-02-23 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10398673B2 (en) 2014-02-10 2019-09-03 Respivant Services GmbH Mast cell stabilizers treatment for systemic disorders
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US10238628B2 (en) 2014-02-10 2019-03-26 Respivant Sciences Gmbh Mast cell stabilizers treatment for systemic disorders
US9758533B2 (en) 2014-04-23 2017-09-12 The Research Foundation For The State University Of New York Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
US10435418B2 (en) 2014-04-23 2019-10-08 The Research Foundation for the State University o Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
US11116800B2 (en) 2014-06-03 2021-09-14 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
US9808491B2 (en) 2014-06-03 2017-11-07 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
US10624843B2 (en) 2014-09-04 2020-04-21 Corium, Inc. Microstructure array, methods of making, and methods of use
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
EP3872063A1 (en) 2014-11-25 2021-09-01 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
WO2016086063A1 (en) 2014-11-25 2016-06-02 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US11590265B2 (en) 2015-02-23 2023-02-28 Biotissue Holdings Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US11691951B2 (en) 2015-02-27 2023-07-04 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US11318169B2 (en) 2015-05-20 2022-05-03 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US10857093B2 (en) 2015-06-29 2020-12-08 Corium, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10596146B2 (en) 2015-08-07 2020-03-24 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10391078B2 (en) 2015-08-07 2019-08-27 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017040617A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
WO2017096304A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
US11707492B2 (en) 2016-01-29 2023-07-25 Biotissue Holdings Inc. Fetal support tissue products and methods of use
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2017197240A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
US11883381B2 (en) 2016-05-12 2024-01-30 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
US11464767B2 (en) 2016-05-25 2022-10-11 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US10463613B2 (en) 2016-08-31 2019-11-05 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10265267B2 (en) 2016-08-31 2019-04-23 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10561635B2 (en) 2016-10-07 2020-02-18 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US10583113B2 (en) 2016-10-07 2020-03-10 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US11786602B2 (en) 2017-11-10 2023-10-17 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
US11147885B2 (en) 2017-11-10 2021-10-19 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
US11110177B2 (en) 2017-11-10 2021-09-07 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
WO2019094772A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
US11833210B2 (en) 2017-11-10 2023-12-05 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
US10632209B2 (en) 2017-11-10 2020-04-28 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2019113469A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
WO2019236957A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
EP4155293A1 (en) 2018-06-07 2023-03-29 The Regents of The University of Michigan Prc1 inhibitors and methods of treatment therewith
US11242325B2 (en) 2018-07-27 2022-02-08 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
US20220152316A1 (en) * 2019-02-25 2022-05-19 Asti Corporation Injection needle
WO2020190890A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics Inc. Nicorandil derivatives
WO2021237068A2 (en) 2020-05-21 2021-11-25 Board Of Regents, The University Of Texas System T cell receptors with vgll1 specificity and uses thereof
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Also Published As

Publication number Publication date
FR2172168A1 (en) 1973-09-28
DK131270B (en) 1975-06-23
ZA73459B (en) 1973-10-31
GB1408925A (en) 1975-10-08
DK131270C (en) 1975-11-17
DE2305989A1 (en) 1973-08-23
CH560544A5 (en) 1975-04-15
JPS4893192A (en) 1973-12-03
BE795384A (en) 1973-08-13
LU67007A1 (en) 1973-04-19
AU5145073A (en) 1974-07-25
BR7301058D0 (en) 1973-12-18
AR195415A1 (en) 1973-10-08
NL7301843A (en) 1973-08-16

Similar Documents

Publication Publication Date Title
US3814097A (en) Dressing
CA1333689C (en) Transdermal drug delivery device
US6461644B1 (en) Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US6096334A (en) Adhesive patch for applying medication to the skin and method
EP1992386B1 (en) Transdermal drug administration apparatus having microneedles
JP5133697B2 (en) Medical device
US6611707B1 (en) Microneedle drug delivery device
US7440798B2 (en) Substance delivery system
US3598122A (en) Bandage for administering drugs
CN101912663B (en) Empty micropin array chip, percutaneous dosing paster, device and manufacture method thereof
CN111388407B (en) Microneedle array based on dopamine gel and preparation and application thereof
US3946734A (en) Apparatus for controlling the release of a drug
JPH03505044A (en) Printed skin-permeable drug administration device
US5827530A (en) Fillable patch for dermal or transdermal delivery
PT85603B (en) TRANSDERMIC THERAPEUTIC SYSTEM AND PROCESS FOR ITS PRODUCTION
US20060015059A1 (en) Substance delivery device
US20180326061A1 (en) Modified transdermal delivery device or patch and method of delivering insulin from said modified transdermal delivery device
JPH01500115A (en) Flat treatment device and its manufacturing method
US20070081977A1 (en) Device for transdermal administration of active substances
US20060163215A1 (en) Process for producing pad based for transdermal drug administration, pad base for transdermal drug administration and needle
US4804541A (en) Transdermal administration using benzyl alcohol
JPS60242864A (en) Parenteral administration system utilizing hollow fiber cellunit
JP5767094B2 (en) Transdermal drug delivery device
KR0143549B1 (en) Improved Percutaneous Delivery Device for Pharmacological Compound Administration Under pH-Controlled Conditions
US5558664A (en) Device for the dermal absorption of medicinal solutes